Top

Anil K. Sood, M.D.

Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery

About Dr. Sood

Dr. Anil K. Sood is Professor and Vice Chair for Translational Research in the Departments of Gynecologic Oncology and Cancer Biology and co-director of the Center for RNA Interference and Non-Coding RNA at the MD Anderson Cancer Center. He is also Director of the multi-disciplinary Blanton-Davis Ovarian Cancer Research Program. Dr. Sood co-leads the Ovarian Cancer Moon Shot Program.

Dr. Sood received his medical degree from the University of North Carolina, Chapel Hill, North Carolina. His research is focused in three main areas: 1) mechanisms of angiogenesis and metastasis in ovarian cancer; 2) effects of neuroendocrine stress hormones on ovarian cancer growth and progression, 3) development of new strategies for systemic in vivo siRNA delivery. Dr. Sood has received major recognition for his research accomplishments including the Hunter Award, the Margaret Greenfield/Carmel Cohen Excellence in Ovarian Cancer Research Prize, and the GCF/Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher. He is an elected member of the American Society for Clinical Investigation (ASCI), the American Association for the Advancement of Science (AAAS), and the Association of American Physicians (AAP). He was appointed as an American Cancer Society Professor in 2017.

Meet Anil Sood, M.D.

In the News

Power blush, bronzer, and eye shadow with makeup brushes

Is talc in makeup safe?

Cancerwise blog post: Dr. Anil Sood discusses ovarian cancer symptoms, diagnosis and treatment, as well as MD Anderson's Ovarian Cancer Moon Shot.

Ovarian cancer diagnosis and treatment: What’s new

Present Title & Affiliation

Primary Appointment

American Cancer Society Professor, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas

Frank McGraw Memorial Chair in Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX

Co-Director, Women's Cancer Moonshot Program, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Director, Blanton-Davis Ovarian Cancer Research Program, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Vice Chairman, Translational Research, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Co-Director, Department of Center for RNA Interference and Non-Coding RNA (Red and Charline McCombs Institute for the Early Detection and Treatment of Cancer), The University of Texas MD Anderson Cancer Center, Houston, Texas

Professor, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor, Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas

Graduate Faculty, Regular Member, Graduate School of Biomedical Sciences, The University of Texas Health Science Center, Houston, TX

Education & Training

Postgraduate Training

1995-1998	Fellow, Gynecologic Oncology, University of Iowa Hospitals and Clinics, Iowa City, Iowa
1991-1995	Resident, Obstetrics and Gynecology, University of Florida, Gainesville, Florida

Licenses & Certifications

2011	NCI Investigator
2002	Texas Medical Board
2001	American Board of Obstetrics and Gynecology, Certification of Special Qualifications in Gynecologic Oncology
1999	American Board of Obstetrics and Gynecology
1993	Florida Licensure
1991	Federation Licensing Examination

Experience & Service

Administrative Appointments/Responsibilities

Co-Director, Women's Cancer Moonshot Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2012 - Present

Director, Blanton-Davis Ovarian Cancer Research Program, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2011 - Present

Vice Chairman, Translational Research, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2010 - Present

Member, Research Council, The University of Texas MD Anderson Cancer Center, Houston, TX, 2009 - 2013

Co-Director, Department of Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2009 - 2022

Director, Journal Club, Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2003 - 2012

Director, Fellow Education, Department of Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, Iowa City, IA, 2000 - 2002

Other Professional Positions

Pelotonia-AACR Women’s Cancer Initiative Scientific Advisory Committee (SAC),, AACR, 2022 - 2025

Board of Directors, Society of Gynecologic Oncology (SGO), 2021 - 2024

Scientific Program Committee, and Co-Chair of Master Session on Ovarian Cancer, International Gynecologic Cancer Society (IGCS) 2022 Annual Global Meeting, 2021 - 2022

Member, Research Management Task Force, SGO, 2020 - 2021

Member, Program Committee and Executive Advisory Board Member, The Nano/Molecular Medicine and Engineering Conference, 2016 - 2018

Member, Scientific Program Committee, 47th Annual Meeting on Women’s Cancer (SGO, 2016), 2015 - 2016

Member, Search Committee for Vice President, Therapeutics Discovery, 2015 - 2016

Member, Institute of Medicine Committee on the State of the Science in Ovarian Cancer Research, 2014 - 2015

Faculty, Vail Methods in Clinical Cancer Research Workshop Sponsored by ASCO and AACR, Vail, CO, 2009 - 2015

External Advisory Board, Mayo Clinic, Rochester, MN, 2009 - 2012

Scientific Program Committee, 11th Biennial Meeting of the International Gynecologic Cancer Society, Santa Monica, CA, 2006 - Present

Chair, Reproductive Scientist Development Program Scholar's Fund Committee, 2006 - 2008

Member, Gynecologic Cancer Scientific Steering Committee (GCSC), National Cancer Institute (NCI), Bethesda, MD, 2006 - 2010

Consultantships, MedImmune, Inc, Gaithersburg, MD, 2005

Committee Member, Preparation of Gynecologic Oncology Written Examination, American Board of Obstetrics and Gynecology, Dallas, TX, 2005 - 2009

Member-at-Large, Western Association of Gynecologic Oncologists, 2003 - 2005

Scientific Program Committee, Western Association of Gynecologic Oncologists, 1999

Candidates Task Force, Society of Gynecologic Oncologists, 1999 - 2002

Extramural Institutional Committee Activities

Member, Executive Oversight Committee for the Advanced Microscopy Core facility, MDACC, The University of Texas MD Anderson Cancer Center, 2022 - Present

Member, Faculty Grievance Oversight Committee, The University of Texas MD Anderson Cancer Center, 2020 - Present

Member, Steering Committee, Cancer Biology Program, UT MD Anderson UTHealth Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, 2017 - Present

Member, Sabin Family Foundation Fellow Award Committee, The University of Texas MD Anderson Cancer Center, 2015 - Present

M.D./Ph.D. Program Board, UTHealth and MD Anderson Cancer Center Graduate School of Biomedical Sciences (GSBS), The University of Texas MD Anderson Cancer Center, 2014 - Present

Member, Advisory Board, CCTS T32, The University of Texas MD Anderson Cancer Center, 2012 - Present

Member, IAB, CCSG, Flow Cytometry / Confocal Microscopy Core Lab, The University of Texas MD Anderson Cancer Center, 2011 - Present

Member, Steering Committee, T32 Training Grant in Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, 2005 - Present

Member, Fellowship Admissions Committee, UT M.D. Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2004 - Present

Member, Executive Committee, Blanton-Davis Ovarian Cancer Research Program, UT M.D. Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2004 - Present

Member, Research Committee, Division of Surgery, UT M.D. Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2003 - Present

Member, Tumor Bank Committee, Department of Gynecologic Oncology, UT M.D. Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2002 - Present

Member, Fellowship Planning Committee, Department of Gynecologic Oncology, UT M.D. Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2002 - Present

Editorial Activities

Editorial Board, Extracellular Vesicles and Circulating Nucleic Acids, 2024 - Present

Editorial Board, SN (Springer-Nature) Comprehensive Clinical Medicine, 2019 - Present

Editorial Board, Investigational New Drugs, 2017 - Present

Associate Editor, Nanomedicine: Nanotechnology, Biology, and Medicine, 2016 - Present

Editorial Board, Non-Coding RNA, 2014 - Present

Editorial Board Member, Journal of Ovarian Research, 2012 - Present

Editorial Board, Cancer Hallmarks, 2011 - 2013

Editorial Board, Frontiers in Genetics (Non-Coding RNA), 2011 - 2024

Associate Editor, Journal of Ovarian Research, 2010 - 2012

Editorial Board, American Journal of Cancer Research, 2010 - Present

Editorial Board, Journal of Clinical Oncology, 2010 - 2012

Editorial Board, International Journal of Women's Health, 2008 - 2015

Deputy Editor, Gynecologic Oncology, 2008 - 2022

Editorial Board, Obstetrics and Gynecology International, 2008 - 2016

Advisory Panel, US Obstetrics and Gynecology, 2007 - 2014

Editorial Board, Gynecologic Oncology, 2006 - 2008

Editorial Board, Obstetrics and Gynecology, 2006 - 2010

Editor, Prognostic and Predictive Factors in Gynecologic Cancers, 2006 - Present

Editorial Board, Cancer Biology and Therapy, 2005 - 2019

Editorial Board, Current Women's Health Reviews, 2004 - Present

Editorial Advisory Board, Cancer, 2003 - 2018

Honors & Awards

2024	Society of Gynecologic Oncology's 2024 Gynecologic Oncology Innovation Award, Society of Gynecologic Oncology
2024	Elected, National Academy of Inventors (NAI), National Academy of Inventors (NAI)
2023	Distinguished Alumnus Award, University of Iowa
2021	Elected, National Academy of Medicine (NAM), National Academy of Medicine (NAM)
2017	Elected, Association of American Physicians (AAP), Association of American Physicians (AAP)
2017	American Cancer Society Research Professor Award, American Cancer Society
2015	Making a Difference Award, The Belinda Sue Fund
2015	Outstanding Achievement Award, Society of American Asian Scientists in Cancer Research (SAASCR)
2014	Rosalind Franklin Ovarian Cancer Research award (Ovarian Cancer National Alliance), Ovarian Cancer National Alliance
2014	Society for Gynecologic Investigation President's Achievement Award, Society for Gynecologic Investigation
2012	Elected Fellow, The American Association for the Advancement of Science
2011 - 2012	America's Top Doctors for Cancer, Castle Connolly Medical Ltd. (U.S. News & World Report rankings)
2011	Dallas/Fort Worth Living Legend Faculty Achievement Award in Basic Research, MD Anderson Cancer Center
2011	GCF/Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher
2010 - 2024	Elected, Fellow of the Academy of Behavioral Medicine, Academy of Behavioral Medicine
2009	Excellence in Teaching Award, Association of Professors of Gynecology and Obstetrics, The University of Texas M.D. Anderson Cancer Center
2009	Elected, The American Society for Clinical Investigation
2008	Elected, Alpha Omega Alpha Honor Medical Society
2008	Elected Fellow, The American Gynecological and Obstetrical Society
2007 - Present	Educator of the month, UT M.D. Anderson Cancer Center
2007	Excellence in Ovarian Cancer Research Award, The Gynecologic Cancer Foundation/Margaret Greenfield/Carmel Cohen, MD
2006 - 2009	Faculty Scholar Award, UT M.D. Anderson Cancer Center
2005	Educator of the Month, UT M.D. Anderson Cancer Center
2005	Invited Speaker, National Cancer Institute, Rockville, MD, Ovarian Cancer State of the Science Meeting - Angiogenesis approaches in ovarian carcinoma
2004 - Present	James F. Nolan Award for the best overall research presentation, Western Association of Gynecologic Oncologists and the Felix Rutledge Society, Monterey, CA
2004	Invited speaker for the Exploring the Integration of Psychoneuroimmunology and Tumor Immunology in Cancer Control Research Conference, Basic Biobehavioral Research Branch (BBRB), N.C.I., Bethesda, Maryland
2003	Outstanding educator, UT M. D. Anderson Cancer Center
2003	Charles A. Hunter, Jr. Prize Thesis Award, The American Gynecological and Obstetrical Society. Functional role of matrix metalloproteinases in ovarian tumor cell plasticity
2002	Invited expert for the Biological Mechanisms of Psychosocial Effects on Disease (BiMPED) Conference, Basic Biobehavioral Research Branch (BBRB), N.C.I., Bethesda, Maryland
2002	James F. Nolan Award for the best overall research presentation, The Annual Meeting of the Western Association of Gynecologic Oncologists, Newport Beach, CA
1998	Young Investigator Award, Fourth Joint Conference of the American Association for Cancer Research (AACR) and the Japanese Cancer Association Meeting
1997	Best All-Around Clinical Poster, The 28th Annual Meeting of the Society of Gynecologic Oncologists (SGO)
1996	J.G. Moore Award, The Annual Meeting of the Western Association of Gynecologic Oncologists, San Diego, CA, Genomic Instability in Ovarian Cancer: A Reassessment Using Arbitrarily Primed Polymerase Chain Reaction
1995	Outstanding Laparoendoscopic Resident Surgeon, University of Florida
1994 - 1995	Outstanding Performance on CREOG Exam Award
1992 - 1995	Outstanding Student Teaching Award, University of Florida

Professional Memberships

National Academy of Inventors

2024 - Present

National Academy of Medicine

2021 - Present

Association of American Physicians

2017 - Present

The American Association for the Advancement of Science

2012 - Present

Academy of Behavioral Medicine Research

2010 - Present

The American Society for Clinical Oncology

2009 - Present

American Gynecological and Obstetrical Society

2009 - Present

American Society for Biochemistry and Molecular Biology (ASBMB)

2009 - Present

American Psychosomatic Society

2003 - Present

Psycho-Neuro-Immunology Research Society, Member

2002 - Present

American College of Surgeons

2002 - Present

International Gynecologic Cancer Society

2002 - Present

Felix Rutledge Society, Member

2002 - Present

Western Association of Gynecologic Oncologists

1999 - Present

Gynecologic Oncology Group

1999 - Present

American Society of Clinical Oncology

1998 - Present

American Association for Cancer Research

1995 - Present

Society of Gynecologic Oncologists

1995 - Present

American College of Obstetricians and Gynecologists

1995 - Present

North Carolina Society Medical Student Section, American Medical Association

1988 - 1991

Selected Presentations & Talks

Local Presentations

2024. Catalyzing change: The ovarian cancer moon shot journey. Invited. NCI Division of Extramural Activities (DEA) Brown Bag Seminar (Online), US.
2024. Therapeutic applications of non-coding RNAs. Invited. 5th Annual Non-Coding RNA Symposium. Chicago, Illinois, US.
2024. Rare tumors. Invited. SGO 2024 Allied Health Professionals Meeting. Charlotte, North Carolina, US.
2024. Unraveling ovarian cancer complexity with spatial analyses. Invited. 31st Annual Precision Med TRI-CON Meeting. San Diego, CA, US.
2024. Therapeutic applications of non-coding RNAs. Invited. Medicine Grand Rounds. Pittsfield, MA, US.
2023. Extracellular vesicles as biomarkers and drivers of biology in ovarian cancer. Invited. Translational and Basic Science Research Program in Early Lesions (TBEL). Houston, Texas, US.
2023. Catalyzing change: Ovarian cancer Moon Shot Journey. Invited. Leaders in the Field Seminar. Los Angeles, CA, US.
2023. Capitalizing on adaptive changes in the tumor microenvironment. Invited. TRANSCEND Cancer Initiative Symposium. Houston, Texas, US.
2023. Opportunities across kingdoms for RNAi delivery. Invited. Gordon Research Conference FNA Nanotechnology: RNA self-assembly, packaging, imaging and therapeutics. Ventura, CA, US.
2022. Effects of neuroendocrine stress hormones on ovarian cancer growth and progression. Invited. Cardiology Grand Rounds. Houston, Texas, US.
2022. Extracellular vesicles as biomarkers and drivers of biology in ovarian cancer. Invited. Cancer Biomarkers in Vesicles & Beyond. Houston, Texas, US.
2022. Emerging opportunities for enhancing immune therapy. Invited. Ovarian cancer Research Group Think Tank Meeting. Denver, CO, US.
2022. Sharpening the scalpel with molecular biology. Invited. International Gynecologic Cancer Society (IGCS) Annual Global Meeting. New York, NY, US.
2022. Updates from the Ovarian Cancer Moon Shot Program. Invited. Kelly Society Lecture. Baltimore, MD, US.
2022. Therapeutic applications of non-coding RNAs. Invited. Seminar (Zoom). West Lafeyette, IN, US.
2021. Overcoming adaptive changes in the tumor micronvironment. Invited. Grand Rounds. Houston, Texas, US.
2021. Understanding the mechanisms of adaptive resistance to anti-angiogenesis drugs. Invited. Grand Rounds. Houston, Texas, US.
2021. Bench-to-bedside (and back): Collaboration between physicians and scientists. Invited. Faculty Development Session. Milwaukee, WI, US.
2021. Overcoming adaptive changes in the tumor microenvironment. Invited. Distinguished Lecture Series in Experimental Therapeutics. Houston, Texas, US.
2020. 1) Lessons learned from the Ovarian Cancer Moon Shot program; 2) The platelet lifeline to cancer. Invited. 2020 Ob/Gyn Residents' and Fellows' Research Day. Rochester, MN, US.
2020. Dangerous liaisons between platelets and cancer. Invited. New Haven, CT, US.
2020. Bench-to-bedside (and back): Adaptive changes in the tumor microenvironment. Invited. The Stephenson Cancer Center 2020 Cancer Research Symposium. Oklahoma City, OK, US.
2019. Stress, nerves, and RNAi therapy. Invited. Distinguished Speakers Seminar Series. Buffalo, NY, US.
2019. Advances and obstacles in RNAi therapy. Invited. 2nd Conference on Biomotors, Virus Assembly, and Nanobiotechnology Applications (in conjunction with Bi-annual Meeting of the International Society of RNA Nanotechnology and Nanomedicine. Columbus, OH, US.
2019. Lessons learned from the Ovarian Cancer Moon Shot Program. Invited. International Ovarian Cancer Research Consortium and International Symposium on Tumor Microenvironment. Oklahoma, OK, US.
2019. The platelet lifeline to cancer. Invited. NCI 7th Molecular and Cellular Characterization of Screen-Detected Lesions (MCL) Consortium. Nashville, TN, US.
2019. Lessons learned from the Ovarian Cancer Moon Shot Program. Invited. Grand Rounds. Boston, MA, US.
2019. Ovarian cancer metastasis: Mechanisms and therapy. Invited. Inaugural Symposium on Cancer Metastasis in Honor of Isaiah J. Fidler, Celebrating 50 years of cancer metastasis research. Houston, Texas, US.
2019. 1) Keynote address - Updates from the ovarian cancer Moon Shot program; 2) Grand rounds - Dangerous liaisons between platelets and cancer. Invited. Gynecologic Oncology Research Retreat. Cleveland, Ohio, US.
2018. Metronomic therapy: Lessons from the lab and clinic. Invited. Sixth International Meeting of Metronomic Chemotherapy in Oncology. Grand Rapids, MI, US.
2018. Overcoming adaptive changes in the tumor microenvironment. Invited. The American Cancer Society Jiler Professors & Fellows Conference. Minneapolis, MN, US.
2018. Therapeutic applications of non-coding RNAs. Invited. Omaha, NE, US.
2018. Dangerous liaisons between platelets and cancer. Invited. Tampa, FL, US.
2018. Emerging opportunities in rare gynecologic cancers. Invited. Workshop on drug development in gynecologic malignancies. Silver Spring, MD, US.
2018. Targeting the tumor microenvironment in ovarian cancer metastasis. In the Session RAOS09 - Ovarian cancer metastasis. Invited. Annual Meeting of the American Association for Cancer Research. Chicago, IL, US.
2018. The platelet lifeline to cancer. Invited. 9th Symposium on Hemostasis: Advances in the clinical and basic sciences of coagulation. Chapel Hill, NC, US.
2018. Personalized surgical algorithm for advanced ovarian cancer. Invited. The Farr Nezhat Surgical Innovation Session on Surgical Decision Making in Advanced Ovarian Cancer. 49th Annual Meeting of Society of Gynecologic Oncology. New Orleans, LA, US.
2018. Dangerous liaisons between platelets and cancer. Invited. Grand Rounds. Bryan, Texas, US.
2018. 1) Therapeutic applications of non-coding RNAs. 2) Dangerous liaisons between platelets and cancer. Invited. Reproductive Sciences Seminar; Ob-Gyn Clinical Grand Rounds. Denver, CO, US.
2018. Dangerous liaisons between platelets and cancer. Invited. Grand Rounds. Houston, Texas, US.
2017. Role of platelets in adaptive changes to anti-angiogenesis therapy. In session on: New Innovations in Platelet Regulation of Tumor Growth and Metastasis. Invited. 59th Annual Meeting of the American Society of Hematology. Atlanta, GA, US.
2017. 1) New drugs for targeted therapy in gynecologic oncology; 2) Crucial conversations: You get what you negotiate; 3) Lessons learned from the ovarian cancer Moon Shot program; 4) Dangerous liaisons between platelets and cancer. Visiting. Ob/Gyn postgraduate conference: Advances in gynecologic cancers. Iowa City, IA, US.
2017. Leveraging the stress response in ovarian cancer management. Invited. State-of-the-Art Ovarian Cancer Conference. New York, NY, US.
2017. Selective targeting of tumor angiogenesis. Invited. 15th International Nanomedicine & Drug Delivery Symposium. Ann Arbor, MI, US.
2017. 1) Crucial conversation: You get what you negotiate; 2) Successful grantsmanship. Invited. SGO Early Career Educational Summit. Chicago, IL, US.
2017. Therapeutic applications of non-coding RNAs. Invited. First Conference on Biomotors, Virus Assembly, and Nanobiotechnology Applications. Columbus, OH, US.
2017. Prolactin and ovarian cancer. Invited. Federation of American Societies for Experimental Biology (FASEB) meeting on "Growth hormone/prolactin family in biology and disease. Steamboat Springs, CO, US.
2017. Systemic in vivo delivery using biocompatible nanoparticles. Invited. 16th Annual World Preclinical Congress. Boston, MA, US.
2017. Emerging concepts in stress, inflammation, and tumor microenvironment. Invited. 24th Annual Scientific Meeting of the PsychoNeuroImmunology Research Society. Galveston, Texas, US.
2017. Multi-level approaches to cancer. Invited. Integrated Multi-Level Approaches to Psychosocial Processes & Health. Boston, MA, US.
2017. Lecture in Gynecology: Dangerous liaisons between platelets and cancer. Invited. The 22nd Annual Robert C. Knapp, M.D. Boston, MA, US.
2017. 1) IOM recommendations, recent advances in ovarian cancer; 2) New directions in targeting angiogenesis. Invited. An AACR Special Conference; Addressing Critical Questions in Ovarian Cancer Research and Treatment. Pittsburgh, PA, US.
2017. Of Zebras and Lions: How stress influences cancer metastasis. Invited. Pennsylvania, PA, US.
2016. A framework for personalized approaches to ovarian cancer. Invited. Sidney Kimmel Cancer Center Grand Rounds. Philadelphia, PA, US.
2016. Ovarian cancer metastasis: Mechanisms and therapy. Invited. Metastatic Cancer Task Force Testimony and Operational Meeting. Tysons Corner, VA, US.
2016. Of Zebras and Lions: How stress influences cancer metastasis. Invited. Center for Pediatric Research Symposium. Sioux Falls, SD, US.
2016. Metabolic fingerprint of stress influences in cancer. Invited. NCI Network on Biobehavioral Pathways in Cancer Capstone Meeting. Rockville, MD, US.
2016. Overcoming adaptive changes in the tumor microenvironment. Invited. The Rivkin Center for Ovarian Cancer and the AACR - 11th Biennial Ovarian Cancer Research Symposium. Seattle, WA, US.
2016. Lessons learned from the Moonshot Program. Invited. Detroit, MI, US.
2016. New approaches for targeting tumor angiogenesis. Invited. Gordon Research Conference: Drug Carriers in Medicine and Biology. Waterville Valley, NH, US.
2016. State of anti-angiogenic therapies and adaptive changes. Invited. SPORE Workshop on Translational Research in Ovarian/GYN Cancers. Shady Grove, Rockville, MD, US.
2016. Promises and challenges of RNAi therapeutics. Invited. Center for Targeted Therapies Seminar Series. Nashville, TN, US.
2016. Stress, nerves and cancer. Invited. Panel on Opportunities for Cancer Prevention during Early Adulthood: Putting Scientific Evidence into Public Health. Atlanta, GA, US.
2016. Emerging approaches for targeted and sustained delivery of ncRNAs. Invited. Workshop on RNA Nanobiology. Rockville, MD, US.
2016. About Trousseau, platelets, angiogenesis, and cancer patients. Invited. Miami, FL, US.
2016. About Trousseau, platelets, angiogenesis and cancer patients. Invited. Molecular Pathology Seminar Series. Baltimore, MD, US.
2015. Hematogenous metastasis of ovarian cancer: Rethinking mode of spread. Invited. An AACR Special Conference on Tumor Metastasis. Austin, Texas, US.
2015. Promises and challenges of RNAi therapeutics. Invited. Symposium on Drug Discovery & Development. Lexington, KY, US.
2015. Promises and challenges of RNAi therapeutics. Invited. Fort Worth, Texas, US.
2015. A framework for personalized approaches to ovarian cancer. Invited. iBRIGHT 2015 (Integrative Biostatics Research for Imaging Genomics, & High-throughput Technologies in Precision Medicine. Houston, Texas, US.
2015. Adaptation to anti-angiogenesis therapy. Invited. An AACR Special Conference on Advances in Ovarian Cancer Research: Exploiting Vulnerabilities. Orlando, FL, US.
2015. A framework for personalized approaches to ovarian cancer. Invited. Biologic Therapeutics Center's Translational Research Seminar Series. St. Louis, MO, US.
2015. Promises and challenges of RNAi therapeutics. Invited. Joint Biologic Therapeutics Center (Washington University) and Chemistry Series (Monsanto) seminar. St. Louis, MO, US.
2015. Adaptation to anti-angiogenesis therapy. Invited. Symposia on cancer Research: Emerging Concepts in Host Response to Cancer. Houston, Texas, US.
2015. Drugging the undruggable: New directions in RNAi therapeutics. Invited. Annual University Retreat for Research, US.
2015. About stress, nerves, and cancer metastasis. Invited. Seattle, WA, US.
2015. Drugging the undruggable: New directions in RNAi therapeutics. Invited. Grand Rounds, CT, US.
2015. Ovarian cancer metastasis: Re-thinking mode of spread. Invited. Department of Pathology Grand Rounds. Detroit, MI, US.
2015. About stress, nerves, and cancer metastasis. Invited. Workshop on the Role of Nerves in Cancer Progression. Rockville, MD, US.
2015. Targeting IncRNA in ovarian cancer. Invited. Cambridge Healthtech Institute's Extracellular Biomarkers Summit. Boston, MA, US.
2015. Small RNAs: From biomarkers to cancer therapy. Invited. Houston, Texas, US.
2015. Molecular predictors of residual disease after cytoreduction. Invited. Symposium on Neoadjuvant chemotherapy for ovarian cancer - Clinical considerations and research opportunities. Gynecologic Oncology Group Winter 2015 Meeting. San Diego, CA, US.
2015. New approaches for targeted and sustained delivery of ncRNAs. Invited. Gordon Research Conference: RNA Nanotechnology. Ventura, CA, US.
2014. About Trousseau, platelets, and ovarian cancer. Invited. Fred Benjamin, MD Memorial Lectureship. New Hyde Park, NY, US.
2014. Unmet Needs for Imaging in Cancer Patients and Cancer Biology. Invited. Workshop on Current Topics in Cancer Systems Biology: Multi-Scale Imaging for Cancer Biology. Houston, Texas, US.
2014. Clinical perspectives of metabolism research. Invited. Symposium on Metabolism in Cancer. Houston, Texas, US.
2014. Drugging the undruggable: New directions in RNAi therapeutics. Invited. Fourth Annual Women's Cancer Research Center Retreat. Pittsburgh, PA, US.
2014. From science to practice: Bridging the gap with translational research. Invited. 4th Annual Postdoctoral Science Symposium. Houston, Texas, US.
2014. Mater microRNA regulatory networks in ovarian cancer. Invited. Systems Medicine and Bioengineering Seminar Series. Houston, Texas, US.
2014. Biological validation of lethality targets using nanotechnology. Invited. 2nd Annual NCI Center for Strategic Scientific Initiatives (CSSI) Science Day. Bethesda, MD, US.
2014. Promises and challenges of RNAi therapeutics. Invited. Reproductive Biology Seminar Series, US.
2014. Nanotechnology from a clinician's point of view. Invited. The 105th Annual Meeting of the American Association for Cancer Research. San Diego, CA, US.
2014. Promises and challenges of RNAi therapeutics. Invited. Cincinnati, Ohio, US.
2014. 1) Crucial conversations: You get what you negotiate; 2) Grantsmanship and Career Development Proposals. Invited. SGO Early Career Educational Summit. Chicago, IL, US.
2013. Causes and consequences of cancer-associated thrombocytosis. Invited. In session on: Platelets and Cancer, 55th Annual Meeting of the American Society of Hematology. New Orleans, LA, US.
2013. Master microRNA regulatory networks in ovarian cancer. Invited. Houston, Texas, US.
2013. New directions in targeting the tumor microenvironment. Invited. New York, NY, US.
2013. About Trousseau, platelets, microenvironment and cancer patients. Invited. New York, NY, US.
2013. Causes and consequences of cancer-associated thrombocytosis. Invited. Fall Research Symposium. Minneapolis, MN, US.
2013. Collection and analysis of "omic" data to provide accurate diagnosis and treatment. Invited. Annual Principal Investigators Meeting. Bathesda, MD, US.
2013. About George Engel and Mechanisms of Stress Effects on Cancer Metastasis. Invited. Annual meeting of the American Gynecological and Obstetrical Society. Chicago, IL, US.
2013. Causes and consequences of paraneoplastic thrombocytosis. Invited. Advances in Ovarian Cancer Research: From Concept to Clinic. Miami, FL, US.
2013. About Trousseau, platelets and ovarian cancer. Invited. Philadelphia, PA, US.
2013. Two new directions: Metformin and stress signaling. Invited. Education Session: Pathways in Gynecologic Malignancies, 2013 Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, US.
2013. Mechanisms of paraneoplastic thrombocytosis. Invited. C.M. Easley Symposium and Resident Research Day. Greenville, SC, US.
2013. Targeting tumor angiogenesis using RNA interference. Invited. Director's Lectureship Series. Albuquerque, NM, US.
2013. Targeting tumor angiogenesis using RNA interference. Invited. 2013 Indiana University Simon Cancer Center's Cancer Research Day. Indianapolis, IN, US.
2013. New directions in targeting the tumor microenvironment. Invited. C.M. Easley Symposium and Resident Research Day. Greenville, SC, US.
2013. Therapeutic gene silencing in vivo using biocompatible nanoparticles. Invited. Symposium: New Tools for Cancer Using Nanomaterials, nanostructures, and Nanodevices. San Francisco, CA, US.
2013. Bad blood: The role of platelets in ovarian carcinoma. Invited. Dana-Farber/Harvard Cancer Center Spring Symposium. Boston, MA, US.
2013. Interfering with tumor vasculature. Invited. Moores Cancer Center Director's Seminar Series. San Diego, CA, US.
2012. Promises and challenges of RNAi therapeutics. Invited. Tumor Microenvironment and Drug Discovery. Oklahoma City, OK, US.
2012. Targeting tumor angiogenesis using RNA interference. Invited. Pathobiology Seminar Series. Chicago, IL, US.
2012. Promises and challenges of RNAi therapeutics. Invited. South Bend, IN, US.
2012. Targeting tumor angiogenesis using RNA interference. Invited. Department of Pharmacology Seminar Series. Galveston, Texas, US.
2012. Neuroendocrine influences on cancer metastasis. Invited. Charlottesville, VA, US.
2012. Neuroendocrine influences on cancer metastasis. Invited. 18th Annual Cancer Research Symposium. Sacramento, CA, US.
2012. Promises and challenges with use of RNA interference for therapy. Invited. 28th Southern Biomedical Engineering Conference. Houston, Texas, US.
2012. Integrated translational research in gynecologic cancers. Invited. Education Forum III: Critical pathways in gynecologic cancers. The 2012 Annual Meeting on Women's Cancer. Austin, Texas, US.
2012. Targeted therapy for ovarian cancer. Invited. Molecular Approaches to Managing Women's Cancers, Baylor College of Medicine/M.D. Anderson Cancer Center Joint Symposium. Houston, Texas, US.
2012. Exploiting ovarian cancer microenvironment and metabolic circuits for therapeutic purposes. Invited. Capitalizing on Biology to Develop Novel Prevention and Treatment Approaches to Gynecologic Cancer, Gynecologic Oncology Group 84th Semi-Annual Meeting. San Diego, CA, US.
2012. Promises and challenges with use of RNA interference for therapy. Invited. 9th Biennial Ovarian Cancer Research Symposium. Seattle, WA, US.
2012. Interfering with tumor vasculature. Invited. Grand Rounds. Boston, MA, US.
2012. Interfering with tumor vasculature. Invited. Grand Rounds. New Orleans, LA, US.
2012. Mechanisms of stress effects on cancer. Invited. Cancer Survivorship Research: Translating Science to Care (6th Biennial Cancer Survivorship Research Conference. Alexandria, VA, US.
2012. Therapeutic gene silencing in vivo using RNA interference. Invited. TechConnect Summit & Expo. Santa Clara, CA, US.
2012. Promises and challenges of RNAi Therapeutics. Invited. 2nd Annual Trainees' Research Retreat. Houston, Texas, US.
2011. Neuroendocrine influences on tumor microenvironment. The Department of Biochemistry and Molecular Biology Seminar Series. Houston, Texas, US.
2011. Interfering with tumor vasculature. Invited. The Mary Jane & George Clymer Ovarian Cancer Research Retreat. Charleston, SC, US.
2011. New directions in anti-angiogenesis therapy. Invited. The 9th International Conference on Ovarian Cancer. Austin, Texas, US.
2011. Neuroendocrine influences on cancer metastasis. Invited. Department of Surgery Grand Rounds. New York, NY, US.
2011. Interfering with tumor vasculature. Invited. New York, NY, US.
2011. Interfering with tumor vasculature. Invited. Roswell Park Cancer Institute Faculty Forum. Buffalo, NY, US.
2011. Neuroendocrine influences on cancer metastasis. Invited. Hematology/Oncology Cancer Epidemiology, Prevention & Control Grand Rounds. Detroit, MI, US.
2011. RNAi therapeutics: Challenges and future directions. Invited. The Leukemia Research Meeting. Houston, Texas, US.
2011. RNAi therapeutics: Translation from bench to bedside. Invited. In: Next-Generation Therapeutic Targets and Drugs: 47th Annual Meeting. Chicago, IL, US.
2011. Stromal influences of stress in cancer: The role of macrophages. Invited. In: NCI Symposium: PNI and Cancer: Role of the Tumor Macro(phage)-Environment. 18th Annual Meeting of the PsychoNeuroImmunology Research Society. Chicago, IL, US.
2011. Stress effects on tumor microenvironment. Invited. In: NCI Symposium: Cancer Mechanisms. Annual Meeting of the Academy of Behavioral Medicine Research. Deer Valley, UT, US.
2011. Neuroendocrine influences on cancer metastasis. Invited. Iowa City, IA, US.
2011. Neuroendocrine influences on cancer metastasis. Invited. In Stress and Disease: Lessons for Research on Cancer. Boston, MA, US.
2011. Interfering with tumor vasculature. Invited. Boston, MA, US.
2011. Targeting the EphA2 axis in uterine carcinoma. Invited. 7th Annual Uterine Cancer Biology Symposium. Houston, Texas, US.
2011. Bad blood: The role of platelets in ovarian carcinoma. Invited. 12th International Forum on Ovarian Cancer, Helene Harris Memorial Trust. Hallandale, FL, US.
2011. Translational Progress Towards personalized Medicine in Gynecologic Cancers. Invited. New Trends in Managing Gynecologic Cancers: The Need for Personalized Medicine. San Diego, CA, US.
2011. Regulation of tumor angiogenesis by EZH2. Invited. The 13th International Symposium on Anti-Angiogenic Agents. San Diego, CA, US.
2011. Molecular targeting of metastatic cancer. Invited. Symposium on Mechanisms and Management of Tumor Metastasis. 58th Annual Meeting of the Society for Gynecologic Investigation. Miami, FL, US.
2011. Neuroendocrine influences on cancer metastasis. Invited. First Annual Kidney Cancer Collaborative Symposium. Houston, Texas, US.
2011. Adrenergic regulation of tumor microenvironment. Invited. In Major Symposium, "Neuroendocrine influences on cancer progression", the 102nd Annual Meeting of the American Society for Cancer Research. Orlando, FL, US.
2011. Translational research: Training and beyond. Invited. In Professional Advancement Series Session, "Translational Research: Where do you fit in and what you need to succeed", the 102nd Annual Meeting of the American Society for Cancer Research. Orlando, FL, US.
2010. New concepts in therapeutic targets and platforms. Invited. SGO's 2010 State of the Art Conference. Chicago, IL, US.
2010. Neuroendocrine Influences on Cancer Metastasis. Invited. Huntsman Cancer Institute Seminar Series. Salt Lake City, UT, US.
2010. Neuroendocrine Influences on Cancer Metastasis. Invited. Program in Hormone Related Malignancies. Denver, CO, US.
2010. Neuroendocrine influences on cancer metastasis. Invited. Epidemiology of Psychological and Social Influences on Cancer Outcome, A Think Tank meeting. Los Angeles, CA, US.
2010. Neuroendocrine Influences on Cancer Metastasis. Invited. Cincinnati, OH, US.
2010. Ovarian Cancer: Clinical Aspects. Invited. Ultrasound in the New Millennium: The Cancer Patient. Houston, Texas, US.
2010. Angiogenesis, Invasion, and Metastasis. Invited. A Primer on Cancer Biology and Plausible Mechanisms and Pathways for Stress-Mediated Effects on Cancer Biology. 68th Annual Meeting of the American Psychosomatic Society. Portland, OR, US.
2010. Systemic Regulation of Tumor Progression II: Sympathetic Nervous System. Invited. A Primer on Cancer Biology and Plausible Mechanisms and Pathways for Stress-Medicated Effects on Cancer Biology. 68th Annual Meeting of the American Psychosomatic Society. Portland, OR, US.
2010. Effects of Chronic Stress on Cancer Metastasis. Invited. First Annual University of Florida Department of Obstetrics and Gynecology Meeting. Orlando, FL, US.
2010. Interfering with Tumor Vasculature. Invited. First Global Congress on NanoEngineering for Medicine and Biology (NEMB), American Society of Mechanical Engineers (ASME). Session on Challenges in Biomedicine for Engineers. Houston, Texas, US.
2010. Neuroendocrine Influences on Cancer Metastasis. Invited. Winston Salem, NC, US.
2009. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kB pathway. Invited. Symposium: Complementary and alternative medicine approaches to health and wellness. The 16th Annual Meeting of the Psychoneuroimmunology Research Society. Breckenridge, CO, US.
2009. Targeting angiogenesis in ovarian carcinoma. Invited. New York, NY, US.
2009. Therapeutic gene silencing in vivo using RNA interference. Invited. New York, NY, US.
2009. New directions in anti-angiogenesis therapy. Invited. Eighth Annual International Conference on Ovarian Cancer. New York, NY, US.
2009. Interfering with tumor vasculature. Invited. Grand Rounds. Morgantown, WV, US.
2009. Angiogenesis and tumor microenvironment in gynecologic malignancies. Invited. Grand Rounds. Madison, WI, US.
2009. Effects of chronic stress on cancer metastasis. Invited. In Educational Session "Biological consequences of stress" Eighth Annual International Conference of Frontiers in Cancer Prevention Research. Houston, Texas, US.
2009. Biological approaches to ovarian cancer therapy. SGO Special Symposia: Ovarian Cancer Translational Research. Prospects for Advances in Genetic Risk Assessment, Screening, and Biological Therapy. Invited. Society of Gynecologists 40th Annual Meeting on Women's Cancer. San Antonio, Texas, US.
2009. SiRNA targeting of the tumor vasculature. Invited. The 11th International Symposium on Anti-Angiogenic Agents. San Diego, CA, US.
2009. Therapeutic targeting of angiogenesis in vivo using RNA interference. Invited. Rochester, MN, US.
2009. Therapeutic targeting of angiogenesis. Invited. Charleston, SC, US.
2009. Therapeutic gene silencing in vivo using RNA interference. Invited. The Screening Technologies branch of the Developmental Therapeutics Program. Frederick, MD, US.
2009. Therapeutic gene silencing in vivo using RNA interference. Invited, US.
2008. Effects of neuroendocrine pathways on ovarian cancer growth and progression. Invited. Biobehavioral Influences on Tumor Biology: Preclinical Models of Neuroendocrine Regulation. Bethesda, MD, US.
2008. Angiogenesis and tumor microenvironment in gynecologic malignancies. Invited. Consensus Conference. Minneapolis, MN, US.
2008. Impact of microenvironment on tumor growth: Mechanisms and targets. Invited. Educational Short Course. The 15th Annual Meeting of the Psychoneuroimmunology Research Society. Madison, WI, US.
2008. Neuroendocrine Influences on Cancer Metastasis. Invited. Chapel Hill, NC, US.
2008. Interfering with cancer: An update on siRNA therapeutics. Invited. The 99th Annual Meeting of the American Association for Cancer Research. San Diego, CA, US.
2008. Therapeutic gene silencing in vivo using RNA interference. Invited. Grand Rounds. Houston, Texas, US.
2008. Selectivity Filters for Molecular Therapy. Invited. Sunrise Session 7: State of the Science - Ovarian Cancer, The 39th Annual Meeting of the Society of Gynecologic Oncologists. Tampa, FL, US.
2008. Therapeutic Targeting of Angiogenesis in vivo using RNA interference. Invited. Experimental Therapeutics Lecture Series. Houston, Texas, US.
2008. On the Horizon: Developing Therapeutics. Invited. 7th Biennial Ovarian Cancer Research Symposium. Seattle, WA, US.
2008. Neuroendocrine influences on cancer metastasis. Invited. St. Louis, MO, US.
2008. Therapeutic targeting of angiogenesis. Invited. St. Louis, MO, US.
2008. Research forecast 2009: Novel therapeutics and developing therapies. Invited. Oncology Nursing Society (ONS) 9th Annual Institutes of Learning Program; Recurrent Ovarian Cancer: Challenges and Management Strategies. Seattle, WA, UM.
2008. Angiogenesis and tumor microenvironment in gynecologic malignancies. Invited. Grand Rounds. Gainesville, FL, US.
2007. Translational Research in Ovarian Carcinoma. Invited. Houston, TX, US.
2007. Antivascular therapy for ovarian cancer. Invited. Grand Rounds. Charlotte, NC, US.
2007. Angiogenesis and tumor microenvironment in gynecologic malignancies. Invited. Grand Rounds. Charlotte, NC, US.
2007. Antivascular therapy for ovarian cancer. Invited. Grand Rounds. Nashville, TN, US.
2007. Emerging anti-angiogenesis strategies for gynecologic malignancies. Invited. The 37th Annual Meeting of the Felix Rutledge Society. Houston, TX, US.
2007. Neuroendocrine Influences on Cancer Metastasis. Invited. Bethesda, MD, US.
2007. Anti-Vascular Therapy for Ovarian Cancer. Invited. Obstetrics and Gynecology Grand Rounds. Detroit, MI, US.
2007. Therapeutic gene silencing in vivo using RNA interference. Invited. Hematology and Medical Oncology Grand Rounds. New York, NY, US.
2007. Influence of Biobehavioral Factors on Tumor Biology: Pathway and Mechanisms. Invited. Integrative Medicine Program Lecture. Houston, Texas, US.
2006. Neuroendocrine influences on tumor growth processes. Short Course, PNI and Disease Processes: Fundamentals and clinical perspectives. Invited. The 13th Annual Meeting of the Psychoneuroimmunology Research Society. Miami, FL, US.
2006. Anti-vascular therapy for ovarian cancer. Invited. Grand Rounds. Los Angeles, CA, US.
2006. Effects of chronic stress on cancer metastasis. Invited. Grand Rounds. Los Angeles, CA, US.
2006. Therapeutic gene silencing in vivo using RNA interference in the session entitled "Dissecting the Genomic Architecture of Cancer. Invited. 97th Annual Meeting of the American Association for Cancer Research. Washington, DC, US.
2006. Principles of Targeted Therapy. Invited. The 37th Annual Meeting of the Society of Gynecologic Oncologists. Palm Springs, CA, US.
2006. Therapeutic gene silencing with siRNA. Plastic Surgery Seminar Series. Houston, Texas, US.
2006. Targeted therapy in ovarian cancer. Invited. 5th Annual Clinical Cancer Update. North Lake Tahoe, CA, US.
2006. Stress and its effect on the treatment of ovarian cancer. Invited. San Diego, CA, US.
2006. Angiogenesis: Emerging therapeutic targets. Invited. Gynecologic Oncology Group Semi-Annual Meeting. San Diego, CA, US.
2005. Therapeutic silencing of EphA2 in ovarian cancer. Invited. Grand Rounds. Columbus, OH, US.
2005. Effects of chronic stress on cancer metastasis. Invited. Columbus, OH, US.
2005. Effects of behavioral factors and stress on tumor microenvironment. Invited. Sixth Annual International Conference on Ovarian Cancer. New York, NY, US.
2005. Therapeutic targeting of EphA2 in ovarian cancer. Invited. San Diego, CA, US.
2005. Antiangiogenic approaches in ovarian carcinoma: Opportunities and challenges. Invited. Ovarian Cancer State of the Science Meeting. Rockville, MD, US.
2005. Therapeutic silencing of EphA2 in ovarian cancer. Invited. Philadelphia, PA, US.
2005. Multidisciplinary models of neuroendocrine modulation of tumor progression: Integrative views and historical perspectives on immunological and non-immunological mechanisms. Invited. The 12th Annual Meeting of the Psychoneuroimmunology Research Society. Denver, CO, US.
2005. Anti-vascular therapy for ovarian carcinoma. Invited. Davis, CA, US.
2005. Molecular biology of ovarian carcinoma. Davis, CA, US.
2005. Modified vertical rectus abdominis myocutaneous (VRAM) flap for pelvic reconstruction. Invited. 2005 Winter Meeting of the Society of Gynecologic Oncologists: Controversies in Gynecologic Oncology, US.
2005. Anti-angiogenic therapy for treatment of ovarian cancer. Invited. The 7th International Symposium on Anti-Angiogenic Agents: Recent Advances and Future Directions in Cell Biology and Clinical Research. San Diego, CA, US.
2005. Co-expression and prognostic relevance of angiogenic markers in advanced epithelial ovarian cancer: A Gynecologic Oncology Group (GOG) study. Invited. The 36th Annual Meeting of the Society of Gynecologic Oncologists. Miami, FL, US.
2004. Neuroendocrine modulation of tumor metastasis. Invited. Teton Village, WY, US.
2004. The seed and soil of cancer metastasis. Invited. Exploring the Integration of Psychoneuroimmunology and Tumor Immunology in Cancer Control Research Conference. Bethesda, Maryland, US.
2004. Cox-2 in ovarian carcinoma. Invited. The 35th Annual Meeting of the Society of Gynecologic Oncologists. San Diego, CA, US.
2003. Angiogenesis and beyond in ovarian carcinoma. Invited. Fourth Annual International Conference on Ovarian Cancer. New York, NY, US.
2003. Functional role of matrix metalloproteinases in ovarian tumor cell plasticity. Charles A. Hunter, Jr. Prize Thesis Award Presentation. Napa, CA, US.
2003. The complexity of tumor vascularity. Invited. Grand Rounds. Houston, Texas, US.
2003. The complexity of tumor vascularity: Role of tumor cell plasticity. Invited. Grand Rounds. Galveston, Texas, US.
2002. Molecular determinants of ovarian cancer plasticity. Invited. Grand Rounds, Florida, US.
2002. Operative notes and dictations. Invited. Resident Lecture Series, Iowa, US.
2002. Genetic Screening for Gynecologic Malignancies. Invited. The 50th Annual College Meeting of the American College Obstetricians and Gynecologists. Los Angeles, CA, US.
2002. Molecular determinants of ovarian cancer plasticity. Invited. Grand Rounds. Houston, Texas, US.
2002. High expression of tumor necrosis factor-related apoptosis-inducting ligand (TRAIL) is associated with favorable survival in ovarian cancer. Invited. The 33rd Annual Meeting of the Society of Gynecologic Oncologists. Miami, FL, US.
2001. Ovarian Cancer: Genetic Insights and Management. Invited. On the Horizon of Oncology Nursing Conference. Des Moines, IA, US.
2001. Benign and malignant vulvar neoplasms. Invited. Sioux City, IA, US.
2001. Genetic screening for ovarian cancer: Medicolegal implications. Invited. Grand Rounds, Iowa, US.
2001. Genetic screening and medicolegal ramifications. Invited. Joint Gynecologic Oncology Conference of Washington University and Saint Louis University. St. Louis, MO, US.
2001. Prophylactic approaches for ovarian cancer. Invited. Grand Rounds. St. Louis, MO, US.
2001. Genetic Insights into Gynecologic Disorders: Genetic screening for gynecologic malignancies. Invited. The 49th Annual College Meeting of the American College of Obstetricians and Gynecologists. Chicago, IL, US.
2001. Genetic Insights into Gynecologic Disorders: Prophylactic options for gynecologic malignancies. Invited. The 49th Annual College Meeting of the American College of Obstetricians and Gynecologists. Chicago, IL, US.
2001. Genetic Insights into Gynecologic Disorders: Future prospects for molecular treatments. Invited. The 49th Annual College Meeting of the American College of Obstetricians and Gynecologists. Chicago, IL, US.
2001. Methods to Repair Obstetric Lacerations. Invited. Resident Lecture Series, Iowa, US.
2000. Genetic screening for women's malignancies. Invited. 7th Annual Current Topics in Ob/Gyn, Women's Malignancies - Year 2000 Update. Rootstown, Ohio, US.
2000. 7th Annual Current Topics in Ob/Gyn Cancer of the ovary: Surgical prevention. Invited. Women's Malignancies - Year 2000 Update. Rootstown, Ohio, US.
2000. Issues in gynecologic cancer: Work-up and treatment of a patient with a pelvic mass. Invited. Ground Rounds. Desk Moines, Iowa, US.
2000. Vasculogenic mimicry in ovarian carcinoma. Invited. Iowa Council Volunteer Board of Directors Meeting. Amana, Iowa, US.
2000. Clinical trials for gynecological malignancies. Invited. Davenport, Iowa, US.
2000. Ovarian cancer vasculogenesis: Clinical and research perspectives. Invited. Charlotte, North Carolina, US.
2000. Evaluation of the bowel function in the postoperative patient. Invited. Resident Lecture Series, Iowa, US.
2000. Clinical trials in ovarian cancer. Invited. Oncology Nursing Society Conference, Iowa, US.
1999. Prophylactic oophorectomy: for whom?. Invited. Postgraduate Conference. Iowa City, Iowa, US.
1999. Issues in gynecologic cancer. Invited. Iowa City, Iowa, US.
1999. Indications for prophylactic oophorectomy. Invited. Ground Rounds. Mason City, Iowa, US.
1999. Gynecologic Cancers. Invited. "Person to Person" live call-in radio show, Iowa, US.
1999. Vulvar neoplasms: Premalignant and malignant. Invited. Des Moines, Iowa, US.
1999. Ovarian cancer: An update. Invited. Grand Rounds. Des Moines, Iowa, US.
1998. Clinical Trials. Invited, Iowa, US.
1998. Ovarian cancer: An update. Invited. Chicago, IL, US.
1998. Menopause in the Cancer Patient. Eleventh Annual Cancer Symposium. Waterloo, Iowa, US.
1998. Repair of Surgical Injuries to Bowel and Urinary Tract. Invited. Resident Lecture Series, Iowa, US.
1998. Ovarian Cancer: The role for primary surgical cytoreduction. Invited. Grand Rounds, Iowa, US.
1997. Management of menopause. Invited. Health Beat Radio Show, Iowa, US.
1997. Ovarian Cancer: Can We Alter Survival of the Fittest. Invited. Grand Rounds, Iowa, US.
1996. Menopausal Concerns in the Oncology Patient. Invited. Scofield Advanced Oncology Nursing Conference. Williamsburg, Iowa, US.
1996. Molecular Prognostic Factors for Breast Cancer. Invited. Grand Rounds, Iowa, US.
1994. Vaginal Adenocarcinoma. Invited. Grand Rounds, US.
1994. Evaluation of a pelvic mass. Invited, Florida, US.
1993. Management of menopause. Invited, Florida, US.

Regional Presentations

2018. Personalized surgical algorithm for advanced ovarian cancer. Invited. The 2018 Regional Meeting of the AAGL. Chongqing, CN.
2011. Therapeutic gene silencing using RNA interference. Invited. 67th Southwest Regional Meeting of the American Chemical Society. Austin, Texas, US.

National Presentations

2024. Promises and challenges of RNAi therapeutics. Invited. Duke Cancer Institute Seminar Series. Durham, NC, US.

International Presentations

2024. Opportunities across kingdoms for RNAi delivery. Invited. Global Conference on Research and Application of Chinese Herbal Medicine-derived Extracellular Vesicles. Guangzhou, CN.
2023. Therapeutic applications of non-coding RNAs. Invited. International Conference on Molecular Oncology and Precision Medicine. Riyadh, SA.
2022. Effects of neuroendocrine stress hormones on ovarian cancer growth and progression. Invited. Global Gynecological Oncology Summit (virtual meeting), CN.
2022. Capitalizing on adaptive changes in the tumor microenvironment. Invited. International Conference on Advanced Biomedical Sciences. Taichung, TW.
2022. 1) Can we detect and overcome PARPi resistance? 2) Capitalizing on vulnerabilities from adaptive changes to anti-angiogenesis drugs. Invited. 23rd European Congress on Gynecological Oncology. Berlin, DE.
2021. Understanding the mechanisms of adaptive resistance to anti-angiogenesis drugs. Invited. 9th CCBIO Annual Symposium 2021 (Virtual). Bergen, NO.
2019. Therapeutic considerations for ovarian carcinomas and adaptive changes. Invited. Tumor seminar on Difficult Questions in Ovarian Cancer Research, Joint meeting of the International Agency for Research on Cancer (IARC) and the NCI. Lyon, FR.
2019. 1) About Trousseau, platelets, angiogenesis, and cancer patients; 2) Updates from the ovarian cancer Moon Shot program. Invited. 61st Annual Meeting of the Japan Society of Gynecologic Oncology (JSGO). Niigata, JP.
2019. Overcoming adaptive changes in the tumor microenvironment. Invited. The 5th Red House Forum, International Obstetrics & Gynecology Summit. Shanghai, CN.
2019. 1) The role and therapeutic implications of thrombocytosis in ovarian cancer; 2) MD Anderson Moon Shot effort in ovarian cancer: Rationale, surgical triage and updates; 3) Adaptive changes from antiangiogenic drugs; 4) New therapeutic strategies: RNA inhibitors and combinations with PARP inhibitors. Invited. Next Frontiers to Cure Cancer Annual Meeting. Sao Paulo, BR.
2019. Overcoming adaptive changes in the tumor microenvironment. Invited. 71st Annual Congress of the Japan Society of Obstetrics and Gynecology. Nagoya, JP.
2019. Overcoming adaptive changes in the tumor microenvironment. Invited. The UT MD Anderson Cancer Center Global Academic Programs and Israel Joint Symposium on Collaborative Cancer Research in the Era of Precision Medicine. Tel Aviv, IL.
2018. Updates from the Ovarian Cancer Moon Shot. Invited. Joint meeting between the European Society of Gynecological Oncology (ESGO - SEGO) and the Felix Rutledge Society (FRS). Barcelona, ES.
2018. Therapeutic applications of non-coding RNAs. Invited. 2nd China International Medical Technology Conference. Lianyungang, CN.
2018. Overcoming adaptive changes in the tumor microenvironment. Invited. Global Academic Programs Conference 2018. Stockholm, SE.
2018. Ovarian cancer moon shot program. Invited. 6th MD Anderson International Meeting in Gynecologic Oncology: Embracing New Standards of Care in Gynecologic Cancers. Madrid, ES.
2018. Overcoming adaptive changes in the tumor microenvironment. Invited. 20th annual MITO meeting. Naples, IT.
2017. 1) Dangerous liaisons between platelets and cancer; 2) Lessons learned from the ovarian cancer Moon Shot Program. Invited. Cambridge, GB.
2017. 1) Updates from the ovarian cancer moon shot program; 2) Dangerous liaisons between platelets and cancer. Invited. 8th Trope - Kolstad meeting: Updates and Controversies in Gynecologic Oncology. Oslo, NO.
2017. Impact of stress on cancer biology. Invited. XXIII Congreso Latinoamericano de Bioquimica Clinica. Punta del Este, UY.
2017. 1) New drugs for targeted therapy in gynecologic oncology; 2) New advances in chemotherapy for ovarian cancer. Invited. The 4th Red House Forum, International Obstetrics & Gynecology Summit. Shanghai, CN.
2017. 1) A framework for personalized approaches to ovarian cancer; 2) Targeting the undruggable: Advances and obstacles in RNAi therapy. Invited. ANZ-GOG Annual Scientific Meeting. Melbourne, AU.
2017. Emerging role of platelets in adaptive changes to anti-angiogenesis therapy. Invited. Gordon Research Conference: Cell Biology of Megakaryocytes & Platelets. Lucca (Barga), IT.
2016. 1) About Trousseau, platelets, angiogenesis and cancer patients; 2) Personalized surgical therapy in ovarian cancer; 3) New drugs for targeted therapy in gynecologic oncology; 4) Peritoneal Carcinomatosis - Role of Hyperthermic intraperitoneal chemotherapy (HIPEC). Invited. 1st South Southeast Congress of Brazilian Society of Surgical Oncology. Florianopolis, BR.
2016. Lessons learned from the Moonshot Program: A team approach to advance patient care. Invited. The 6th MD Anderson Cancer Center - China Sister Institute Pathology Conference. Shanghai, CN.
2016. Pathologist-surgeon communications on frozen section diagnosis. Invited. The 6th MD Anderson Cancer Center - China Sister Institute Pathology Conference. Shanghai, CN.
2016. Lessons learned from the Moonshot program. Invited. Copenhagen, DK.
2016. Drugging the undruggable: New directions in RNAi therapeutics. Invited. Tel Aviv, IL.
2016. Drugging the undruggable: new directions in RNAi therapeutics. Invited. 8th Canadian Conference of Ovarian Cancer Research. Niagra, Ontario, CA.
2016. Clinical and Translational Pathways. Invited. Bergen, NO.
2016. Targeting stress neuroendocrine pathways in cancer. Invited. 5th MD Anderson International Meeting in Gynecologic Oncology: Tailoring Cancer-Therapy in the Era of Personalized Medicine. Madrid, ES.
2016. Predictors of residual disease in patients with ovarian cancer. Invited. 5th MD Anderson International Meeting in Gynecologic Oncology: Tailoring Cancer-Therapy in the Era of Personalized Medicine. Madrid, ES.
2016. Targeting angiogenesis in ovarian cancer: Overcoming adaptive responses. Invited. 5th MD Anderson International Meeting in Gynecologic Oncology: Tailoring Cancer-Therapy in the Era of Personalized Medicine. Madrid, ES.
2016. Framework for overcoming resistance. Invited. Cancer Translational Research Initiative Planning Workshop. Toronto, CA.
2015. A framework for personalized approaches to ovarian cancer. Invited. 4th Oncosalud International Symposium. Lima, PE.
2015. Novel agents for targeted therapy in gynecologic oncology. Invited. 4th Oncosalud International Symposium. Lima, PE.
2015. A framework for personalized approaches to ovarian cancer. Invited. The 3rd International Red House Forum. Shanghai, CN.
2015. What have we learned from the Cancer Genome Atlas. Invited. The 3rd International Red House Forum. Shanghai, CN.
2015. A framework for personalized approaches to ovarian cancer. Invited. 3rd Lowy Symposium - Drug Discovery to Personalized Medicine. Sydney, AU.
2015. Promises and challenges of RNAi therapeutics. Invited. Molecular Pathways to Therapeutics: Paradigms and Challenges in Oncology. Mumbai, IN.
2015. Hematogenous metastasis of ovarian cancer. Invited. Helene Harris Memorial Trust, 13th International Forum on Ovarian Cancer. Toledo, ES.
2014. Targeting stress signaling in ovarian cancer. Invited. Ovarian Cancer: A Comprehensive Symposium on Medical and Surgical Management. Medellin, CO.
2014. Novel developments in targeted therapy in advanced epithelial ovarian cancer. Invited. Ovarian Cancer: A Comprehensive Symposium on Medical and Surgical Management. Medellin, CO.
2014. Master microRNA regulatory networks in ovarian cancer. Invited. Emerging Trends in Gene/Cell-Based Therapeutics and Nanocarriers for Drug Discovery. Shanghai, CN.
2014. Neuroendocrine influences on cancer metastasis. Invited. The Second Hunan Provincial Forum on Gynecology Oncology. Changsha, CN.
2014. President's Achievement Award Presentation: Targeting the undruggable: New directions in RNA interference and tumor microenvironment. Invited. 61st Annual Meeting of the Society of Gynecologic Investigation. Florence, IT.
2014. New directions in targeting the tumor microenvironment. Invited. Milan, IT.
2014. RNAi strategies in future therapeutics of ovarian cancer. Invited. IV MD Anderson International Meeting in Gynecologic Oncology: Emerging Therapies in Gynecological Cancer. Madrid, ES.
2014. The cancer genome atlas (TCGA): Innovations in ovarian and uterine cancer. Invited. IV MD Anderson International Meeting in Gynecologic Oncology: Emerging Therapies in Gynecological Cancer. Madrid, ES.
2013. Anti-angiogenesis therapy for ovarian cancer: Moving beyond VEGF. Invited. The 3rd Biennial Meeting of the Asian Society of Gynecologic Oncology. Kyoto, JP.
2013. What have we learned from the cancer genome atlas?. Invited. The 3rd Biennial Meeting of the Asian Society of Gynecologic Oncology. Kyoto, JP.
2013. New directions in targeting the tumor microenvironment. Invited. Niigata, JP.
2013. Personalized therapy in gynecologic oncology: Biology, strategy, and assessment. Invited. 18th International Meeting of the European Society of Gynecological Oncology (ESGO). Liverpool, GB.
2013. Promises and challenges of RNAi therapeutics. Invited. 2nd International Michelangelo Conference: Promises and Challenges of Developing New Drugs in Oncology. Milan, IT.
2013. Neuroendocrine influences on cancer metastasis. Invited. 2nd Red House International Obstetrics and Gynecology Peak Forum. Shanghai, CN.
2013. Promises and challenges of RNAi therapeutics. Invited. 10th Annual Oncology Research & Education Day,. London,, Ontario, CA.
2012. Targeting tumor angiogenesis using RNA interference. Invited. Oligonucleotide Delivery: Biology, Engineering and Development. Hernstein, AT.
2012. Targeting tumor microenvironment in gynecologic cancers. Invited. In Educational Symposium: What is individualized medicine? The 14thth Biennial Meeting of the International Gynecologic Cancer Society (IGCS). Vancouver, CA.
2012. Translational research in gynecological oncology. Invited. The 14th Biennial Meeting of the International Gynecologic Cancer Society (IGCS). Vancouver, CA.
2012. Integrated genomic analysis in ovarian cancer: The Cancer Genome Atlas. Invited. Molecular Biology of Gynecologic Cancers: The Basic Principles of Translational Research. III M. D. Anderson International Conference in Gynecologic Oncology. Madrid, ES.
2012. Novel agents for targeted therapy in gynecologic oncology. Invited. Molecular Biology of Gynecologic Cancers: The Basic Principles of Translational Research. III M. D. Anderson International Conference in Gynecologic Oncology. Madrid, ES.
2012. Small interfering RNA: Promises for treatment and problems in delivery. Invited. Delivering on the Promise of the Human Genome Project. 178th Meeting of the American Association for the Advancement of Science. Vancouver, CA.
2011. Interfering with tumor vasculature. Invited. Oxford, GB.
2010. Microenvironment and pathogenesis of epithelial ovarian cancer. Invited. The Sixth International Symposium on Hormonal Oncogenesis. Tokyo, JP.
2010. Molecular and Biological Effects of Stress on Cancer Metastasis. Invited. NCI Symposium: The role of host factors in the development and progression of neoplastic disease> The 17th Annual Meeting of the Psychoneuroimmunology Research Society. Dublin, IE.
2010. Novel Therapies in Ovarian Cancer. Invited. II M. D. Anderson International Conference in Gynecologic Oncology. Madrid, ES.
2009. Therapeutic gene silencing in vivo using RNA interference. Invited. 4th International Liposome Society Conference: Liposome Advances: Progress in Drug and Vaccine Discovery. London, GB.
2009. Targeted gene silencing in vivo using rHDL nanoparticles. Invited. 4th International Liposome Society Conference: Liposome Advances: Progress in Drug and Vaccine Discovery. London, GB.
2009. Angiogenesis as a therapeutic target in gynecologic malignancies. Invited. Fertility 2009 (6th Biannual Conference of the UK Fertility Societies). Edinburgh, GB.
2009. Therapeutic gene silencing in vivo using RNA interference. Invited. Tel Aviv, IL.
2009. Interfering with tumor vasculature. Invited. Mayaguez, PR.
2009. Therapeutic gene silencing in vivo using RNA interference. Invited. Gyeongju City, KR.
2009. Toxicities of targeted therapy. Invited. The 8th Korean Gynecologic Oncology Group Meeting. Daegu, KR.
2009. Effects of neuroendocrine pathways on ovarian cancer growth and progression. Invited. The 8th Korean Gynecologic Oncology Group Meeting. Daegu, KR.
2009. Anti-angiogenesis agents. Invited. The 24th Annual Meeting of the Korean Society of Gynecologic Oncology and Colposcopy. Daegu, KR.
2009. Emerging therapeutic approaches. Invited. The 24th Annual Meeting of the Korean Society of Gynecologic Oncology and Colposcopy. Daegu, KR.
2008. Neuroendocrine influences on cancer metastasis. Invited. From Molecules to Societies: The Psychobiological Determinants of Health and Well-Being Workshop. British Columbia, CA.
2006. Angiogenesis mechanisms in ovarian cancer. Invited. 1st International Conference on Ovarian Cancer: State of the Art an Future Directions, GR.

Formal Peers

2016. A framework for personalized approaches to ovarian cancer. Invited. Philadelphia, PA, US.
2016. “Of Zebras and Lions: How stress influences cancer metastasis.”. Invited. Philadelphia, PA, US.
2016. Metabolic fingerprint of stress influences in cancer. Invited. Rockville, MD, US.
2016. “Of Zebras and Lions: How stress influences cancer metastasis.”. Invited. Sioux Falls, SD, US.
2016. Of Zebras and Lions: How stress influences cancer metastasis. Invited. Sioux Falls, SD, US.
2016. Lessons learned from the Moonshot program. Invited. Detroit, MI, US.
2016. About Trousseau, platelets, angiogenesis, and cancer patients. Invited. Baltimore, MD, US.
2015. Promises and challenges of RNAi therapeutics. Invited. Fort Worth, TX, US.
2015. A framework for personalized approaches to ovarian cancer. Invited. St. Louis, MO, US.
2015. Promises and challenges of RNAi therapeutics. Invited. St. Louis, MO, US.
2015. Ovarian cancer metastasis: Re-thinking mode of spread. Invited. Detroit, MI, US.
2014. Fred Benjamin, MD Memorial Lectureship, “About Trousseau, platelets, and ovarian cancer.”. Visiting. New Hyde Park, NY, US.
2014. About Trousseau, platelets, and ovarian cancer. Invited. New Hyde Park, NY, US.
2014. “Promises and challenges of RNAi therapeutics.”. Invited. Durham, NC, US.
2014. “Drugging the undruggable: New directions in RNAi therapeutics.”. Invited. Pittsburgh, PA, US.
2014. “Targeting stress signaling in ovarian cancer.”. Invited. Medellin, CO.
2014. “Novel developments in targeted therapy in advanced epithelial ovarian cancer.”. Invited, CO.
2014. “Master microRNA regulatory networks in ovarian cancer.”. Invited. Houston, TX, US.
2014. “Biological validatin of lethality targets using nanotechnology.”. Invited. Bethesda, MD, US.
2014. “Neuroendocrine influences on cancer metastasis”. Invited, CN.
2014. “Nanotechnology from a clinician’s point of view”. Application of nanotechnology to the treatment of cancer patients. Invited. San Diego, CA, US.
2014. “Master microRNA regulatory networks in ovarian cancer”. Invited, CN.
2014. “Promises and challenges of RNAi therapeutics.” , . Invited. Dallas, TX, US.
2014. “New directions in targeting the tumor microenvironment”. Invited. Milan, IT.
2014. President’s Achievement Award presentation: Targeting the undruggable: New directions in RNA interference and tumor microenvironment. Invited. Florence, IT.
2014. President’s Achievement Award presentation: Targeting the undruggable: New directions in RNA interference and tumor microenvironment. , , Italy. March, 2014. Visiting, IT.
2014. Promises and challenges of RNAi therapeutics. Invited. Cincinnati, OH, US.
2013. New directions in targeting the tumor microenvironment. Invited. New York, NY, US.
2013. About Trousseau, platelets, microenvironment and cancer patients. Invited. New York, NY, US.
2013. Causes and consequences of cancer-associated thrombocytosis. Visiting. Minneapolis, MN, US.
2013. Collection and analysis of “omic” data to provide accurate diagnosis and treatment. Invited. Bethesda, MD, US.
2013. Causes and consequences of paraneoplastic thrombocytosis. Invited. Miami, FL, US.
2013. About George Engel and Mechanisms of Stress Effects on Cancer Metastasis. Invited. Chicago, IL, US.
2013. About Trousseau, platelets and ovarian cancer. Invited. Philadelphia, PA, US.
2013. “Promises and challenges of RNAi therapeutics”. Invited. Milan, US.
2013. Promises and challenges of RNAi therapeutics. Invited. London, US.
2013. “Neuroendocrine influences on cancer metastasis”. Invited. Shanghai, US.
2013. “Two new directions: Metformin and stress signaling". Invited. Chicago, IL, US.
2013. Smith-Errington Lecture, Promises and challenges of RNAi therapeutics. Visiting. London.
2013. “Targeting tumor angiogenesis using RNA interference". Invited. Indianapolis, IN, US.
2013. “New directions in targeting the tumor microenvironment”. ,. Invited. Greenville, SC, US.
2013. “Mechanisms of paraneoplastic thrombocytosis”. Invited. Greenville, SC, US.
2013. “Targeting tumor angiogenesis using RNA interference. Invited. Albuquerque, NM, US.
2013. “Therapeutic gene silencing in vivo using biocompatible nanoparticles”. Invited. San Francisco, CA, US.
2013. “Bad blood: The role of platelets in ovarian carcinoma.”. Invited. Boston, US.
2013. “Interfering with tumor vasculature.”. Invited. San Diego, CA, US.
2012. Promises and challenges of RNAi therapeutics. Invited. Oklahoma City, OK, US.
2012. “Promises and challenges of RNAi therapeutics”. Invited. South Bend, IN, US.
2012. Targeting tumor angiogenesis using RNA interference. Invited. Chicago, IL, US.
2012. Targeting tumor angiogenesis using RNA interference. Invited. Galveston, TX, US.
2012. Neuroendocrine influences on cancer metastasis. Invited. Charlottesville, VA, US.
2012. Neuroendocrine influences on cancer metastasis. Invited. Sacramento, CA, US.
2012. Targeted therapy for ovarian cancer. Invited. Houston, TX, US.
2012. Interfering with tumor vasculature. Invited. New Orleans, LA, US.
2012. Interfering with tumor vasculature. Invited. Boston, MA, US.
2012. Promises and challenges with use of RNA interference for therapy. Invited. Seattle, WA, US.
2011. Interfering with tumor vasculature. Invited. Charleston, SC, US.
2011. Neuroendocrine influences on tumor microenvironment. Invited. Houston, TX, US.
2011. Neuroendocrine influences on cancer metastasis. Visiting. New York, NY, US.
2010. Neuroendocrine Influences on Cancer Metastasis. Invited. Salt Lake City, UT, US.
2010. Neuroendocrine Influences on Cancer Metastasis. Invited. Denver, CO, US.
2010. Neuroendocrine Influences on Cancer Metastasis. Invited. Cincinnati, OH, US.
2010. Effects of Chronic Stress on Cancer Metastasis. Invited. Orlando, FL, US.
2010. Neuroendocrine Influences on Cancer Metastasis. Invited. Winston Salem, NC, US.
2009. Interfering with Tumor Vasculature. Invited. Mayaguez, PR.
2009. New directions in anti-angiogenesis therapy. Invited. New York, NY, US.
2009. "Therapeutic targeting of angiogenesis in vivo using RNA interference". Invited. Rochester, MN, US.
2009. "Therapeutic targeting of angiogenesis". Invited. Charleston, SC, US.
2009. "Therapeutic gene silencing in vivo using RNA interference". Invited. Frederick, MD, US.
2009. "Therapeutic gene silencing in vivo using RNA interference". Invited, PA, US.
2009. "Interfering with tumor vasculature". Invited. Mayaguez, PR.
2009. "Therapeutic gene silencing in vivo using RNA interference". Invited, PA, US.
2009. "Therapeutic gene silencing in vivo using RNA interference". Invited. Gyeongju City, KR.
2009. "Therapeutic targeting of angiogenesis in vivo using RNA interference". Invited. Rochester, MN, US.
2009. "Therapeutic targeting of angiogenesis". Invited. Charleston, SC, US.
2009. Targeting angiogenesis in ovarian carcinoma. Invited. New York, NY, US.
2009. Therapeutic gene silencing in vivo using RNA interference. Invited. New York, NY, US.
2009. Interfering with tumor vasculature. Invited. Morgantown, WV, US.
2009. Angiogenesis and tumor microenvironment in gynecologic malignancies. Invited. Madison, WI, US.
2008. Neuroendocrine influences on cancer metastasis. Invited, Vancouver, BC, CA.
2008. "Effects of neuroendocrine pathways on ovarian cancer growth and progression". Invited. Bethesda, MD, US.
2008. Angiogenesis and tumor microenvironment in gynecologic malignancies. Invited. Minneapolis, MN, US.
2008. Therapeutic gene silencing in vivo using RNA interference. Invited. Houston, TX, US.
2008. Neuroendocrine Influences on Cancer Metastasis. Invited. Chapel Hill, NC, US.
2008. "Therapeutic gene silencing in vivo using RNA interference". Invited. San Francisco, CA, US.
2008. "Therapeutic targeting of angiogenesis". Invited. St. Louis, MO, US.
2008. Probstein Lecturer, "Neuroendocrine influences on cancer metastasis". Visiting. St. Louis, MO, US.
2008. Probstein Lecturer, "Therapeutic targeting of angiogenesis". Visiting. St. Louis, MO, US.
2008. "Angiogenesis and tumor microenvironment in gynecologic malignancies". Invited. Gainesville, FL, US.
2008. "Neuroendocrine influences on cancer metastasis". Invited. St. Louis, MO, US.
2007. "Antivascular therapy for ovarian cancer". Invited. Charlotte, NC, US.
2007. "Angiogenesis and tumor microenvironment in gynecologic malignancies". Invited. Charlotte, NC, US.
2007. "Antivascular therapy for ovarian cancer". Invited. Nashville, TN, US.
2007. "Neuroendocrine Influences of Cancer Metastasis". Invited. Bethesda, MD, US.
2007. "Anti-Vascular Therapy for Ovarian Cancer". Invited. Detroit, MI, US.
2007. "Therapeutic Gene Silencing In Vivo using RNA Interference". Invited. New York, NY, US.
2007. "Therapeutic Targeting of Focal Adhesion Kinase (FAK) using In Vivo RNA Interference". Invited. Reno, NV, US.
2007. "Effects of chronic stress on cancer growth and progression". Invited. Bethesda, MD, US.
2007. "Role of VEGF and angiogenesis in gynecologic cancer". Invited. Atlanta, GA, US.
2006. "Neuroendocrine influences on cancer metastasis". Invited. San Francisco, CA, US.
2006. "Anti-vascular therapy in ovarian carcinoma". Invited. Los Angeles, CA, US.
2006. "Effects of chronic stress on cancer metastasis". Invited. Los Angeles, CA, US.
2005. "Effects of chronic stress on cancer metastasis". Invited. Columbus, OH, US.
2005. "Therapeutic silencing of Eph2 in ovarian cancer". Invited. Columbus, OH, US.
2005. "Therapeutic silencing of Eph2 in ovarian cancer". Invited. San Diego, CA, US.
2005. "Therapeutic Targeting of Eph2 in Ovarian Carcinoma". Invited. Philadelphia, PA, US.
2005. "Molecular biology of ovarian carcinoma". Invited. Davis, CA, US.
2005. "Anti-vascular therapy for ovarian carcinoma". Invited. Davis, CA, US.
2002. "Molecular determinants of ovarian cancer plasticity". Invited. Gainesville, FL, US.
2001. "Ovarian Cancer: Genetic Insights and Management". Invited. Iowa City, IA, US.
2001. "Genetic screening for ovarian cancer: Medicolegal implications". Invited. Iowa City, IA, US.
2001. "Benign and malignant vulvar neoplasms". Invited. Sioux City, IA, US.
2001. "Genetic screening and medicolegal ramifications". Invited. St. Louis, MO, US.
2001. "Prophylactic approaches for ovarian cancer". Invited. St. Louis, MO, US.
2001. "Methods to Repair Obstetric Lacerations". Invited. Iowa City, IA, US.
2000. "Issues in gynecologic cancer: Work-up and treatment of a patient with a pelvic mass". Invited. Des Moines, IA, US.
2000. "Vasculogenic mimicry in ovarian carcinoma". Invited. Amana, IA, US.
2000. "Clinical trials for gynecological malignancies". Invited. Davenport, IA, US.
2000. "Ovarian cancer: Clinical and research perspectives". Invited. Charlotte, NC, US.
2000. "Clinical trials in ovarian cancer". Invited. Des Moines, IA, US.
2000. "Evaluation of the bowel function in the postoperative patient". Invited. Iowa City, IA, US.
1999. "Prophylactic Oophorectomy: For Whom?". Invited. Iowa City, IA, US.
1999. "Issues in Gynecologic Cancer". Invited. Iowa City, IA, US.
1999. "Vulvar neoplasms: Premalignant and malignant". Invited. Des Moines, IA, US.
1999. "Ovarian cancer: An update". Invited. Des Moines, IA, US.
1999. "Indications for prophylactic oophorectomy". Invited. Mason City, IA, US.
1999. "Gynecologic Cancers". Invited. Iowa City, IA, US.
1998. "Clinical Trials". Invited. Iowa City, IA, US.
1998. "Ovarian cancer: An update". Invited. Chicago, IL, US.
1998. "Menopause in the Cancer Patient". Invited. Waterloo, IA, US.
1998. "Repair of Surgical Injuries to Bowel and Urinary Tract". Invited. Iowa City, IA, US.
1998. "Ovarian Cancer: The role for primary surgical cytoreduction". Invited. Iowa City, IA, US.
1997. "Management of Menopause". Invited. Iowa City, IA, US.
1997. "Ovarian Cancer: Can We Alter Survival of the Fittest". Invited. Iowa City, IA, US.
1996. "Menopausal Concerns in the Oncology Patient". Invited. Williamsburg, IA, US.
1996. "Molecular Prognostic Factors for Breast Cancer". Invited. Iowa City, IA, US.
1994. "Vaginal Adenocarcinoma". Invited. Gainesville, FL, US.
1994. "Evaluation of a pelvic mass". Invited. Gainesville, FL, US.
1993. "Management of the menopause". Invited. Gainesville, FL, US.

Less

Grant & Contract Support

Date:	2025 - 2026
Title:	Green Medicine: Plant Vesicles in Cancer Treatment
Funding Source:	Lydia Hill Philanthropies
Role:	PI
ID:	FP00023072

Date:	2025 - 2030
Title:	Development of the MasSpec Pen Technology to Guide Surgical Decisions in the Care for Patients with Ovarian Cancer
Funding Source:	BCM/NIH
Role:	PI
ID:	R01 CA306089

Date:	2025 - 2026
Title:	Overcoming adaptive resistance to tisotumab vedotin in gynecologic cancers
Funding Source:	Pfizer
Role:	PI
ID:	LS2025-00064478

Date:	2025 - 2027
Title:	Mapping the Molecular Landscape of Mucinous Ovarian Cancer: Unveiling Tumor-Stroma Dynamics
Funding Source:	Mucinous Ovarian Cancer Coalition (MOCC)
Role:	PI
ID:	AWD00009079

Date:	2024 - 2028
Title:	Platelet Pathophysiology in Resistance to Antiangiogenic Therapy Against Ovarian Cancer Evaluated in a Vascularized TME-Chip
Funding Source:	DOD
Role:	PI
ID:	OC230122P1

Date:	2024 - 2028
Title:	Innovative cell therapy approaches for hematological and solid malignancies
Funding Source:	CPRIT
Role:	Co-PI
ID:	RP240439

Date:	2024 - 2027
Title:	Treatment planning of ADC therapy for ovarian cancer with molecular photoacoustic-ultrasonic imaging
Funding Source:	CPRIT
Role:	Co-I
ID:	RP240311

Date:	2024 - 2026
Title:	AI-guided single-cell transfer learning model to predict precision medicine in ovarian cancer
Funding Source:	Ovarian Cancer Research Alliance (OCRA)
Role:	PI
ID:	CRDGAI-2024-3-1387

Date:	2023 - 2028
Title:	The University of MD Anderson Cancer Center Spore in Ovarian Cancer
Funding Source:	NIH/NCI
Role:	PI
ID:	P50 CA217685 (Bast and Sood)

Date:	2023 - 2028
Title:	Novel Biomarkers Predicting Blood Clots in Ovarian Cancer
Funding Source:	NIH
Role:	PI
ID:	CA275762

Date:	2022 - 2026
Title:	Defining mechanisms of immune suppression via special transcriptomics
Funding Source:	American Cancer Society
Role:	PI
ID:	RP21-155-06COUN

Date:	2021 - 2023
Title:	Theranostic Heterodimer Eph-Targeting Peptides for Ovarian & Breast Cancer
Funding Source:	Emerson Collective Cancer Research Fund
Role:	PI
ID:	710509-80-124339-19

Date:	2021 - 2026
Title:	Multimodal imaging and therapy of Ovarian Cancer
Funding Source:	University of Maryland
Role:	PI
ID:	R01CA247224

Date:	2021 - 2024
Title:	Rational combination therapy with EGFL6 antibodies
Funding Source:	Top Alliance Biosciences Inc
Role:	PI
ID:	AWD00005900

Date:	2021 - 2026
Title:	Training of Academic Gynecologic Oncologists
Funding Source:	NIH/NCI
Role:	PI
ID:	CA101642

Date:	2021 - 2023
Title:	Understanding and targeting myeloid populations in ovarian cancer for enhancing therapeutics effects
Funding Source:	The University of Arkansas
Role:	PI
ID:	813467

Date:	2020 - 2021
Title:	RA200395 - Rational restoration of p53-dependent antitumor drug response in chemoresistant rare ovarian cancer subtype
Funding Source:	Department of Defense (DOD)
Role:	Collaborator
ID:	GRANT13249696

Date:	2019 - 2022
Title:	Rational development of immune therapy for low-grade ovarian serous carcinoma to overcome MEK inhibitor resistance
Funding Source:	DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role:	Co-I
ID:	OC180177 (Wong, KK)

Date:	2019 - 2023
Title:	Development and application of a scalable workflow for immunomagnetic separation of exRNA carrier subclasses and molecular analysis of their cargo
Funding Source:	University of California San Diego/NIH
Role:	Co-I
ID:	1UG3 CA241687 (Laurent, L)

Date:	2019 - 2026
Title:	Cancer Center Support (Core) Grant
Funding Source:	NIH/NCI
Role:	Co-Leader
ID:	P30 CA016672 (Pisters)

Date:	2019 - 2024
Title:	Role of RNA activation in Tumor Progression and Metastasis
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01 CA22907 (Chaluvally-Raghavan)

Date:	2019 - 2021
Title:	Blocking Adaptive Resistance to Anti-Angiogenesis Drugs
Funding Source:	DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role:	Co-I
ID:	OC180136 (Hu, Wei)

Date:	2018 - 2024
Title:	Platelets promote growth of ovarian cancer
Funding Source:	NIH/NCI
Role:	Co-I
ID:	R01 CA177909

Date:	2018 - 2023
Title:	Targeting Stromal Influences on Glutamine Addiction in Ovarian Cancer
Funding Source:	University of Michigan
Role:	Co-I
ID:	R01 CA227622 (Nagrath)

Date:	2018 - 2021
Title:	Mass Spectrometry Imaging to Uncover Predictive Metabolic Markers of Ovarian Cancer Surgical Outcome and Treatment Response
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	RP180381 (Eberlin)

Date:	2017 - 2024
Title:	Harnessing the power of exosomes for non-coding RNA delivery
Funding Source:	NCI
Role:	PI
ID:	R35 CA209904-02

Date:	2017 - 2022
Title:	Targeted Therapeutics for Ovarian Cancer and Its Microenvironment - treatment and theoretical modeling
Funding Source:	NIH/NCI
Role:	Co-PI
ID:	U01 CA213759 (MPI; Lopez)

Date:	2017 - 2021
Title:	Non-coding RNA Cancer Therapeutics
Funding Source:	American Cancer Society (ACS)
Role:	PI
ID:	RP-16-240-01-TBG

Date:	2016 - 2021
Title:	EphA2 targeting in uterine carcinoma (Project 3 - UT MDACC SPORE in Uterine Cancer)
Funding Source:	NIH/NCI
Role:	PI
ID:	P50 CA098258

Date:	2016 - 2019
Title:	Targeting adaptive changes following anti-angiogenesis therapy in ovarian cancer
Funding Source:	Gateway Foundation
Role:	Co-PI
ID:	G-16-100 (Sood)

Date:	2016 - 2021
Title:	Biobehavioral Influences on Ovarian Cancer Progression. Role of Chemoresistance
Funding Source:	NIH/NCI
Role:	Co-I
ID:	R01CA193249

Date:	2015 - 2019
Title:	Targeting adaptive changes following anti-angiogenesis therapy in ovarian cancer
Funding Source:	V Foundation
Role:	Co-PI
ID:	VFoundation-2015 (Sood, Coleman)

Date:	2015 - 2018
Title:	Microenvironmental control of premalignant lesions in ovarian cancer
Funding Source:	Ovarian Cancer Research Fund Alliance, Inc
Role:	Principal Investigator-MDACC

Date:	2014 - 2018
Title:	Selective Tumor Delivery of Anti-Cancer Agents in Ovarian Cancer Therapy
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	DP 150091 (Lacko)

Date:	2014 - 2017
Title:	Ovarian Cancer: Mechanisms of neuroendocrine regulation
Funding Source:	NIH/NCI
Role:	PI
ID:	2R01-CA109298-10

Date:	2013 - 2018
Title:	Platelets Promote Growth of Ovarian Cancer
Funding Source:	NIH/NCI
Role:	Co-I
ID:	R01 CA177909-01 (Afshar-Karghan)

Date:	2013 - 2018
Title:	Novel Extra Cellular RNA-based Combinatorial RNA Inhibition Therapy
Funding Source:	NIH/NCI
Role:	Co-I
ID:	UH3 TR000943

Date:	2013 - 2016
Title:	Consortium to Study Long-Term Survivors of Ovarian Cancer
Funding Source:	Development of Ovarian Cancer Outcome Consortium
Role:	PI
ID:	OC120547

Date:	2013 - 2017
Title:	Power of Platelets in ovarian cancer
Funding Source:	Ovarian Cancer Research Fund
Role:	Principal Investigator-MDACC

Date:	2011 - 2018
Title:	Clinical Translation of Therapeutic siRNA in Solid Malignancies
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	RP120214 (Coleman)

Date:	2011 - 2013
Title:	Disrupting BRCA1/2 DNA Damage Response by Blocking the Centrosomal Protein STIL(SIL): A novel strategy for treatment of ovarian cancer
Funding Source:	Department of Defense (DOD)
Role:	Co-PI
ID:	OC100237

Date:	2011 - 2017
Title:	Circumventing Platinum Resistance Using siRNA Transfer
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Principal Investigator-MDACC
ID:	RP110595-P2

Date:	2011 - 2013
Title:	Role of platelets in ovarian cancer pathogenesis
Funding Source:	BCM/MDACC MRP
Role:	PI

Date:	2010 - 2017
Title:	Texas Center for Cancer Nanomedicine
Funding Source:	NIH/NCI
Role:	PI
ID:	1U54 CA151668-01

Date:	2010 - 2013
Title:	New Reagents for Synthesis of High Potency siRNAs
Funding Source:	Department of Defense (DOD)
Role:	Co-I
ID:	R44 GM084442-03

Date:	2010 - 2016
Title:	Targeting Dll4-Notch signaling in ovarian cancer (Project 2 - UT MDACC SPORE in Ovarian Cancer)
Funding Source:	NIH/NCI
Role:	PI
ID:	NIH 2 P50 CA083639-11

Date:	2010 - 2015
Title:	Molecular Targeting of PPAR-delta in colon cancer
Funding Source:	NIH/NCI
Role:	Co-I
ID:	R01 CA142969-01A1

Date:	2010 - 2013
Title:	Identification and Validation of Biomarkers for Predicting Response to VEGF-Targeted Therapy
Funding Source:	Department of Defense (DOD)
Role:	PI
ID:	W81XWH-10-1-0158

Date:	2009 - 2014
Title:	Biobehavioral-cytokine interactions in ovarian cancer
Funding Source:	NIH/NCI
Role:	Co-I
ID:	R01-CA1045-01 (Supplement

Date:	2009 - 2014
Title:	Toward individualized breast cancer therapy: leveraging molecular medicine with multistage vector technology
Funding Source:	DoD/BCRP
Role:	Co-I
ID:	W81XWH-08-BCRP-INNOV

Date:	2009 - 2013
Title:	Novel siRNA based therapeutic approaches for ovarian carcinoma Program Project Development Grant
Funding Source:	Ovarian Cancer Research Fund
Role:	PI

Date:	2008 - 2012
Title:	Nanovectors for Characterization and Destruction of Breast Tumor Vasculature
Funding Source:	NIH/NCI
Role:	Co-PI
ID:	R01-CA128797

Date:	2006 - 2015
Title:	Anti-vascular therapy for ovarian cancer
Funding Source:	The Marcus Foundation
Role:	PI

Date:	2005 - 2008
Title:	Novel siRNA based therapeutic approaches for ovarian carcinoma, Program Project Development Grant
Funding Source:	Ovarian Cancer Research Fund, Inc
Role:	PI

Date:	2005 - 2010
Title:	Cell-specific targeting of ovarian cancer vasculature SPORE (Project 2)
Funding Source:	NIH
Role:	PI
ID:	CA083639-06A1

Date:	2004 - 2006
Title:	Anti-Vascular effects of AVE8062 in ovarian carcinoma
Funding Source:	Sanofi-Aventis, Inc
Role:	PI

Date:	2004 - 2006
Title:	Biobehavioral-cytokine interactions in ovarian cancer
Funding Source:	NIH/NCI
Role:	Co-I
ID:	R01-CA1045-01 (Supplement)

Date:	2004 - 2011
Title:	Tumor metastasis: Biobehavioral mechanisms
Funding Source:	National Cancer Institute - NIH
Role:	PI
ID:	5R01-CA110793-05

Date:	2004 - 2008
Title:	Role of EphA2 in Ovarian Cancer Development and Progression
Funding Source:	Department of Defense Ovarian Cancer Research Program
Role:	PI
ID:	W81XWH-04-1-0227

Date:	2003 - 2004
Title:	Role of Focal Adhesion Kinase on Taxotere activity in ovarian cancer
Funding Source:	Aventis, Inc
Role:	PI

Date:	2002 - 2004
Title:	Functional Role of MMPs in Ovarian Tumor Cell Plasticity Properties
Funding Source:	UT M.D. Anderson Cancer Center Ovarian Cancer SPORE Career Development Award
Role:	PI

Date:	2002 - 2004
Title:	Neuroendocrine Regulation of VEGF and IL-6 in Ovarian Carcinoma
Funding Source:	The Donna Marie Cimitile Fotheringham Award for Ovarian Cancer Research
Role:	PI

Date:	2001 - 2002
Title:	Role of FAK expression in Invasion and Cisplatin Resistance in Ovarian Cancer
Funding Source:	Gynecologic Cancer Foundation - National Ovarian Cancer Coalition Award
Role:	PI

Date:	2001 - 2005
Title:	Molecular Mechanisms of Ovarian Cancer Plasticity
Funding Source:	Reproductive Scientist Development Program
Role:	PI

Date:	2001 - 2002
Title:	Development of teaching materials regarding operative dictations for residents and medical students
Funding Source:	Council on Teaching, University Iowa
Role:	PI

Date:	2001 - 2002
Title:	Hormonal stimulation of tumor angiogenesis in ovarian cancer
Funding Source:	Oberman Center for Advanced Studies Interdisciplinary Research Grant
Role:	Co-PI

Date:	2000 - 2002
Title:	Biobehavioral-Immune Interactions in Ovarian Cancer
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	R21 CA88293-01

Date:	2000
Title:	ON-Q Pain Management System in Patients Undergoing Abdominal Surgery for Gynecologic Malignancies
Funding Source:	Ethicon Endo-Surgical (EES)
Role:	Co-PI

Date:	1999 - 2001
Title:	A Randomized, Double-Blind, Placebo-Controlled, Phase IIB Study of the Safety and Efficacy of OVAREX (TM) Mab-B43.13 in Ovarian Cancer Patients with an Elevated Serum CA 125 but without Other Evidence of Disease
Funding Source:	ALTAREX Corporation
Role:	PI

Date:	1999 - 2001
Title:	Phase II Trial of Intraperitoneal Topotecan/Oral Etoposide in Ovarian Cancer
Funding Source:	SmithKline Beecham, Inc
Role:	PI

Date:	1999 - 2001
Title:	Molecular Mechanisms Resulting in Distant Metastases in Ovarian Cancer
Funding Source:	Reproductive Scientist Development Program
Role:	PI

Date:	1998 - 1999
Title:	Distant Metastases in Ovarian Cancer
Funding Source:	American Cancer Society Seed Grant
Role:	PI

Date:	1997 - 1998
Title:	Genomic Instability: Why the Guardian Fails in Ovarian Cancer
Funding Source:	ACOG/Ortho Academic Training Fellowship Grant
Role:	Co-PI

Date:	1997 - 1998
Title:	The Use of Anorectal Manometry to Assess Rectal Dysfunction in Patients following Radical Hysterectomy
Funding Source:	American Cancer Society Seed Grant to Dr. Ingrid Nygaard
Role:	Co-PI

Date:	1992 - 1993
Title:	Human Papillomavirus (HPV) DNA in LEEP Plume
Funding Source:	Southern Medical Association Research Project Grant
Role:	Co-I

Date:	1988 - 1989
Title:	Type Specific Detection of Human Papilomavirus (HPV) in Cervical Neoplasia
Funding Source:	Southern Medical Association Research Project Grant
Role:	Co-I

Selected Publications

Peer-Reviewed Articles

Stur, E, Peng, F, Teng, PN, Bayraktar, E, Hu, M, Corvigno, S, Brown, DJ, Lee, S, Moore, KN, Bateman, NW, Darcy, KM, Maxwell, GL, P. Conrads, T, Sahni, N, Vázquez-García, I, Shah, S, Celestino, J, D. Fleming, N, Navin, N, Wang, L, Sood, AK. The dynamic immune behavior of primary and metastatic ovarian carcinoma. npj Precision Oncology 9(1), 2025. e-Pub 2025. PMID: 40281242.
Bateman, NW, Abulez, T, Soltis, AR, McPherson, A, Choi, S, Garsed, DW, Pandey, A, Tian, C, Hood, BL, Conrads, KA, Teng, PN, Oliver, J, Gist, G, Mitchell, D, Litzi, T, Tarney, CM, Crothers, BA, Mhawech-Fauceglia, P, Dalgard, C, Wilkerson, MD, Pierobon, M, Petricoin, EF, Yan, C, Meerzaman, D, Bodelon, C, Wentzensen, N, Lee, JS, Huntsman, DG, Shah, S, Shriver, CD, Phippen, NT, Darcy, KM, Bowtell, DD, Conrads, TP, Maxwell, GL, Makohon-Moore, S, Barakat, W, Zhang, X, Hunt, AL, Ao, W, Lytle-Gabbin, SL, Casablanca, Y, Hamilton, CA, Newell, M, Wells, J, Sukumar, G, Bacikova, D, Freyman, J, Cohn, DE, Berchuck, A, Havrilesky, LJ, Duska, L, Odunsi, A, Sood, AK, Brenton, JD, Sala, E, Annunziata, C, Dorigo, O, Nelson, B, Cochrane, DR, Moore, K, Baldelli, E, Chen, QR, Hu, Y, Fereday, S, Traficante, N, Defazio, A, Goode, EL. Proteogenomic analysis of enriched HGSOC tumor epithelium identifies prognostic signatures and therapeutic vulnerabilities. npj Precision Oncology 8(1), 2024. e-Pub 2024. PMID: 38480868.
Czopik, A, McNamee, EN, Vaughn, V, Huang, X, Bang, IH, Clark, T, Wang, Y, Ruan, W, Nguyen, T, Masterson, JC, Tak, E, Frank, S, Collins, CB, Li, H, Rodriguez-Aguayo, C, Lopez Berestein, G, Gerich, ME, Furuta, GT, Yuan, X, Sood, AK, De Zoeten, EF, Eltzschig, H. HIF-2α-dependent induction of miR-29a restrains TH1 activity during T cell dependent colitis. Nature communications 15(1), 2024. e-Pub 2024. PMID: 39271652.
Murray, CE, Kornepati, AV, Ontiveros, C, Liao, YJ, de la Peña Avalos, B, Rogers, CM, Liu, Z, Deng, Y, Bai, HY, Kari, S, Padron, AS, Boyd, JT, Reyes, R, Clark, CA, Svatek, RS, Li, R, Hu, Y, Wang, M, Conejo-Garcia, JR, Byers, LA, Ramkumar, K, Sood, AK, Lee, JM, Burd, CE, Vadlamudi, RK, Gupta, HB, Zhao, W, Dray, E, Sung, P, Curiel, TJ. Tumour-intrinsic PDL1 signals regulate the Chk2 DNA damage response in cancer cells and mediate resistance to Chk1 inhibitors. Molecular cancer 23(1), 2024. e-Pub 2024. PMID: 39478560.
Lutgendorf SK, Telles RM, Whitney B, Thaker PH, Slavich GM, Goodheart MJ, Penedo FJ, Noble AE, Cole SW, Sood AK, Corn BW. The biology of hope: Inflammatory and neuroendocrine profiles in ovarian cancer patients. Brain Behav Immun 116:362-369, 2024. e-Pub 2024. PMID: 38081436.
Hinchcliff EM, Knisely A, Adjei N, Fellman B, Yuan Y, Patel A, Xu C, Westin SN, Sood AK, Soliman PT, Shafer A, Fleming ND, Gershenson DM, Vikram R, Bathala T, Vining D, Ganeshan DM, Lu KH, Sun CC, Meyer LA, Jazaeri AA. Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer. Cancer 130(7):1061-1071, 2024. e-Pub 2024. PMID: 38009662.
How JA, Legarreta AF, Handley KF, Fellman B, Foster KI, Glassman D, Vuttaradhi VK, Brodsky AL, Lawson B, Frumovtiz M, Westin SN, Ramondetta LM, Gershenson DM, Sood AK, Hillman RT. Serial cytoreductive surgery and survival outcomes in recurrent adult-type ovarian granulosa cell tumors. Am J Obstet Gynecol 230(5):544.e1-544.e13, 2024. e-Pub 2024. PMID: 38191019.
Knisely A, Hinchcliff E, Fellman B, Mosley A, Lito K, Hull S, Westin SN, Sood AK, Schmeler KM, Taylor JS, Huang SY, Sheth RA, Lu KH, Jazaeri AA. Phase 1b study of intraperitoneal ipilimumab and nivolumab in patients with recurrent gynecologic malignancies with peritoneal carcinomatosis. Med 5(4):311-320.e3, 2024. e-Pub 2024. PMID: 38471508.
Ghosh LD, Mathur T, Tronolone JJ, Chuong A, Rangel K, Corvigno S, Sood AK, Jain A. Angiogenesis-Enabled Human Ovarian Tumor Microenvironment-Chip Evaluates Pathophysiology of Platelets in Microcirculation. Adv Healthc Mater:e2304263, 2024. e-Pub 2024. PMID: 38553940.
Corvigno S, Badal S, Spradlin ML, Keating M, Pereira I, Stur E, Bayraktar E, Foster KI, Bateman NW, Barakat W, Darcy KM, Conrads TP, Maxwell GL, Lorenzi PL, Lutgendorf SK, Wen Y, Zhao L, Thaker PH, Goodheart MJ, Liu J, Fleming N, Lee S, Eberlin LS, Sood AK. In situ profiling reveals metabolic alterations in the tumor microenvironment of ovarian cancer after chemotherapy. NPJ Precis Oncol 7(1):115, 2023. e-Pub 2023. PMID: 37923835.
Zhang X, Yao J, Li X, Niu N, Liu Y, Hajek RA, Peng G, Westin S, Sood AK, Liu J. Targeting polyploid giant cancer cells potentiates a therapeutic response and overcomes resistance to PARP inhibitors in ovarian cancer. Sci Adv 9(29):eadf7195, 2023. e-Pub 2023. PMID: 37478190.
Foster KI, Flores Legarreta A, Kamat R, Handley KF, Glassman D, How JA, Lawson BC, Westin SN, Ramondetta LM, Frumovitz M, Gershenson DM, Sood AK, Hillman RT. Clinical outcomes of leuprolide acetate in the treatment of recurrent ovarian granulosa cell tumors. Am J Obstet Gynecol 228(6):724.e1-724.e9, 2023. e-Pub 2023. PMID: 36907533.
Li X, Zhong Y, Zhang X, Sood AK, Liu J. Spatiotemporal view of malignant histogenesis and macroevolution via formation of polyploid giant cancer cells. Oncogene 42(9):665-678, 2023. e-Pub 2023. PMID: 36596845.
Zhang X, Yao J, Niu N, Li X, Liu Y, Huo L, Euscher ED, Wang H, Bell D, Sood AK, Wang G, Lawson BC, Ramalingam P, Malpica A, Sahin AA, Ding Q, Liu J. SOX17: A Highly Sensitive and Specific Immunomarker for Ovarian and Endometrial Carcinomas. Mod Pathol 36(2):100001, 2023. e-Pub 2023. PMID: 36853778.
LaFargue CJ, Amerov P, Noh K, Mangala S, Lu C, Cho M, Pradeep S, Wan Y, Hu W, Rupaimoole R, Coleman RL, Zhang N, An Z, Lopez-Bernstein G, De Franciscis V, Sood AK. Overcoming adaptive resistance to anti-VEGF therapy by targeting CD5L. Nature Communications 14(1), 2023. e-Pub 2023. PMID: 37100807.
Lutgendorf SK, Thaker PH, Goodheart MJ, Arevalo JMG, Chowdhury MA, Noble AE, Dahmoush L, Slavich GM, Penedo FJ, Sood AK, Cole SW. Biobehavioral factors predict an exosome biomarker of ovarian carcinoma disease progression. Cancer 128(23):4157-4165, 2022. e-Pub 2022. PMID: 36251340.
Jensen DM, Han P, Mangala LS, Lopez-Berestein G, Sood AK, Liu J, Kriegel AJ, Usa K, Widlansky ME, Liang M. Broad-acting therapeutic effects of miR-29b-chitosan on hypertension and diabetic complications. Mol Ther 30(11):3462-3476, 2022. e-Pub 2022. PMID: 35965413.
Handley KF, Sims TT, Bateman NW, Glassman D, Foster KI, Lee S, Yao J, Yao H, Fellman BM, Liu J, Lu Z, Conrads KA, Hood BL, Barakat W, Zhao L, Zhang J, Westin SN, Celestino J, Rangel KM, Badal S, Pereira I, Ram PT, Maxwell GL, Eberlin LS, Futreal PA, Bast RC, Fleming ND, Conrads TP, Sood AK. Classification of High-Grade Serous Ovarian Cancer Using Tumor Morphologic Characteristics. JAMA Netw Open 5(10):e2236626, 2022. e-Pub 2022. PMID: 36239936.
Chu YY, Chen MK, Wei Y, Lee HH, Xia W, Wang YN, Yam C, Hsu JL, Wang HL, Chang WC, Yamaguchi H, Jiang Z, Liu C, Li CF, Nie L, Chan LC, Gao Y, Wang SC, Liu J, Westin SN, Lee S, Sood AK, Yang L, Hortobagyi GN, Yu D, Hung MC. Targeting the ALK-CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex. Nat Cancer 3(10):1211-1227, 2022. e-Pub 2022. PMID: 36253486.
Rodriguez-Aguayo C, Bayraktar E, Ivan C, Aslan B, Mai J, He G, Mangala LS, Jiang D, Nagaraja AS, Ozpolat B, Chavez-Reyes A, Ferrari M, Mitra R, Siddik ZH, Shen H, Yang X, Sood AK, Lopez-Berestein G. Corrigendum to "PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis" [EBioMedicine 40 (2019) 290-304]. EBioMedicine 83:104194, 2022. e-Pub 2022. PMID: 35914489.
Wen Y, Chelariu-Raicu A, Umamaheswaran S, Nick AM, Stur E, Hanjra P, Jiang D, Jennings NB, Chen X, Corvigno S, Glassman D, Lopez-Berestein G, Liu J, Hung MC, Sood AK. Endothelial p130cas confers resistance to anti-angiogenesis therapy. Cell Rep 38(4):110301, 2022. e-Pub 2022. PMID: 35081345.
Wong KK, Bateman NW, Ng CW, Tsang YTM, Sun CS, Celestino J, Nguyen TV, Malpica A, Hillman RT, Zhang J, Futreal PA, Rojas C, Conrads KA, Hood BL, Dalgard CL, Wilkerson MD, Phippen NT, Conrads TP, Maxwell GL, Sood AK, Gershenson DM. Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors. Journal of Translational Medicine 20(1), 2022. e-Pub 2022. PMID: 36528667.
Salcedo MP, Sood AK, Jhingran A, Eifel PJ, Klopp AH, Iyer RB, Fellman BM, Jimenez C, Schmeler KM. Pelvic fractures and changes in bone mineral density after radiotherapy for cervical, endometrial, and vaginal cancer: A prospective study of 239 women. Cancer 126(11):2607-2613, 2020. e-Pub 2020. PMID: 32125711.
Bast RC, Matulonis UA, Sood AK, Ahmed AA, Amobi AE, Balkwill FR, Wielgos-Bonvallet M, Bowtell DDL, Brenton JD, Brugge JS, Coleman RL, Draetta GF, Doberstein K, Drapkin RI, Eckert MA, Edwards RP, Elias KM, Ennis D, Futreal A, Gershenson DM, Greenberg RA, Huntsman DG, Ji JXY, Kohn EC, Iavarone C, Lengyel ER, Levine DA, Lord CJ, Lu Z, Mills GB, Modugno F, Nelson BH, Odunsi K, Pilsworth JA, Rottapel RK, Powell DJ, Shen L, Shih IM, Spriggs DR, Walton J, Zhang K, Zhang R, Zou L. Critical Questions in Ovarian Cancer Research and Treatment: Report of an American Association for Cancer Research Special Conference. Cancer 125(12):1963-1972, 2019. e-Pub 2019. PMID: 30835824.
McGuire MH, Herbrich SM, Dasari SK, Wu SY, Wang Y, Rupaimoole R, Lopez-Berestein G, Baggerly KA, Sood AK. Pan-cancer genomic analysis links 3'UTR DNA methylation with increased gene expression in T cells. EBioMedicine. e-Pub 2019. PMID: 31056473.
Ma S, Pradeep S, Villar-Prados A, Wen Y, Bayraktar E, Mangala LS, Kim MS, Wu SY, Hu W, Rodriguez-Aguayo C, Leuschner C, Liang X, Ram PT, Schlacher K, Coleman RL, Sood AK. GnRH-R-Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition. Mol Cancer Ther 18(5):969-979, 2019. e-Pub 2019. PMID: 30926640.
Sans M, Zhang J, Lin JQ, Feider CL, Giese N, Breen MT, Sebastian K, Liu J, Sood AK, Eberlin LS. Performance of the MasSpec Pen for Rapid Diagnosis of Ovarian Cancer. Clin Chem 65(5):674-683, 2019. e-Pub 2019. PMID: 30770374.
Gunaratne PH, Pan Y, Rao AK, Lin C, Hernandez-Herrera A, Liang K, Rait AS, Venkatanarayan A, Benham AL, Rubab F, Kim SS, Rajapakshe K, Chan CK, Mangala LS, Lopez-Berestein G, Sood AK, Rowat AC, Coarfa C, Pirollo KF, Flores ER, Chang EH. Activating p53 family member TAp63: A novel therapeutic strategy for targeting p53-altered tumors. Cancer. e-Pub 2019. PMID: 31012964.
An J, Du Y, Fan X, Wang Y, Ivan C, Zhang XG, Sood AK, An Z, Zhang N. EGFL6 promotes breast cancer by simultaneously enhancing cancer cell metastasis and stimulating tumor angiogenesis. Oncogene 38(12):2123-2134, 2019. e-Pub 2019. PMID: 30455428.
Radhakrishnan R, Ha JH, Jayaraman M, Liu J, Moxley KM, Isidoro C, Sood AK, Song YS, Dhanasekaran DN. Ovarian cancer cell-derived lysophosphatidic acid induces glycolytic shift and cancer-associated fibroblast-phenotype in normal and peritumoral fibroblasts. Cancer Lett 442:464-474, 2019. e-Pub 2019. PMID: 30503552.
Villar-Prados A, Wu SY, Court KA, Ma S, LaFargue C, Chowdhury MA, Engelhardt MI, Ivan C, Ram PT, Wang Y, Baggerly K, Rodriguez-Aguayo C, Lopez-Berestein G, Ming-Yang S, Maloney DJ, Yoshioka M, Strovel JW, Roszik J, Sood AK. Predicting novel therapies and targets: Regulation of Notch3 by the bromodomain protein BRD4. Mol Cancer Ther 18(2):421-436, 2019. e-Pub 2019. PMID: 30420565.
Rodriguez-Aguayo C, Bayraktar E, Ivan C, Aslan B, Mai J, He G, Mangala LS, Jiang D, Nagaraja AS, Ozpolat B, Chavez-Reyes A, Ferrari M, Mitra R, Siddik ZH, Shen H, Yang X, Sood AK, Lopez-Berestein G. PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis. EBioMedicine 40:290-304, 2019. e-Pub 2019. PMID: 30655206.
Hisamatsu T, McGuire M, Wu SY, Rupaimoole R, Pradeep S, Bayraktar E, Noh K, Hu W, Hansen JM, Lyons Y, Gharpure KM, Nagaraja AS, Mangala LS, Mitamura T, Rodriguez-Aguayo C, Eun YG, Rose J, Bartholomeusz G, Ivan C, Lee JS, Matsuo K, Frumovitz M, Wong KK, Lopez-Berestein G, Sood AK. PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer. Mol Cancer Ther 18(1):162-172, 2019. e-Pub 2019. PMID: 30305341.
Kanlikilicer P, Bayraktar R, Denizli M, Rashed MH, Ivan C, Aslan B, Mitra R, Karagoz K, Bayraktar E, Zhang X, Rodriguez-Aguayo C, El-Arabey AA, Kahraman N, Baydogan S, Ozkayar O, Gatza ML, Ozpolat B, Calin GA, Sood AK, Lopez-Berestein G. Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer. EBioMedicine 38:100-112, 2018. e-Pub 2018. PMID: 30487062.
Byeon Y, Lee JW, Choi WS, Won JE, Kim GH, Kim MG, Wi TI, Lee JM, Kang TH, Jung ID, Cho YJ, Ahn HJ, Shin BC, Lee YJ, Sood AK, Han HD, Park YM. CD44-Targeting PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer. Cancer Res 78(21):6247-6256, 2018. e-Pub 2018. PMID: 30115698.
Kim GH, Won JE, Byeon Y, Kim MG, Wi TI, Lee JM, Park YY, Lee JW, Kang TH, Jung ID, Shin BC, Ahn HJ, Lee YJ, Sood AK, Han HD, Park YM. Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer. Drug Deliv 25(1):1394-1402, 2018. e-Pub 2018. PMID: 29890852.
Dood RL, Zhao Y, Armbruster SD, Coleman RL, Tworoger S, Sood AK, Baggerly KA. Defining Survivorship Trajectories Across Patients With Solid Tumors: An Evidence-Based Approach. JAMA Oncol 4(11):1519-1526, 2018. e-Pub 2018. PMID: 29860375.
Yuan J, Hu Z, Mahal BA, Zhao SD, Kensler KH, Pi J, Hu X, Zhang Y, Wang Y, Jiang J, Li C, Zhong X, Montone KT, Guan G, Tanyi JL, Fan Y, Xu X, Morgan MA, Long M, Zhang Y, Zhang R, Sood AK, Rebbeck TR, Dang CV, Zhang L. Integrated Analysis of Genetic Ancestry and Genomic Alterations across Cancers. Cancer Cell 34(4):549-560.e9, 2018. e-Pub 2018. PMID: 30300578.
Inoue K, Deng Z, Chen Y, Giannopoulou E, Xu R, Gong S, Greenblatt MB, Mangala LS, Lopez-Berestein G, Kirsch DG, Sood AK, Zhao L, Zhao B. Bone protection by inhibition of microRNA-182. Nat Commun 9(1):4108, 2018. e-Pub 2018. PMID: 30291236.
Haldar R, Shaashua L, Lavon H, Lyons YA, Zmora O, Sharon E, Birnbaum Y, Allweis T, Sood AK, Barshack I, Cole S, Ben-Eliyahu S. Perioperative inhibition of β-adrenergic and COX2 signaling in a clinical trial in breast cancer patients improves tumor Ki-67 expression, serum cytokine levels, and PBMCs transcriptome. Brain Behav Immun 73:294-309, 2018. e-Pub 2018. PMID: 29800703.
Kanikarla-Marie P, Kopetz S, Hawk ET, Millward SW, Sood AK, Gresele P, Overman M, Honn K, Menter DG. Bioactive lipid metabolism in platelet "first responder" and cancer biology. Cancer Metastasis Rev 37(2-3):439-454, 2018. e-Pub 2018. PMID: 30112590.
Umamaheswaran S, Dasari SK, Yang P, Lutgendorf SK, Sood AK. Stress, inflammation, and eicosanoids: an emerging perspective. Cancer Metastasis Rev 37(2-3):203-211, 2018. e-Pub 2018. PMID: 29948328.
Armer JS, Clevenger L, Davis LZ, Cuneo M, Thaker PH, Goodheart MJ, Bender DP, Dahmoush L, Sood AK, Cole SW, Slavich GM, Lutgendorf SK. Life stress as a risk factor for sustained anxiety and cortisol dysregulation during the first year of survivorship in ovarian cancer. Cancer 124(16):3401-3408, 2018. e-Pub 2018. PMID: 29905941.
Gharpure KM, Pradeep S, Sans M, Rupaimoole R, Ivan C, Wu SY, Bayraktar E, Nagaraja AS, Mangala LS, Zhang X, Haemmerle M, Hu W, Rodriguez-Aguayo C, McGuire M, Mak CSL, Chen X, Tran MA, Villar-Prados A, Pena GA, Kondetimmanahalli R, Nini R, Koppula P, Ram P, Liu J, Lopez-Berestein G, Baggerly K, S Eberlin L, Sood AK. FABP4 as a key determinant of metastatic potential of ovarian cancer. Nat Commun 9(1):2923, 2018. e-Pub 2018. PMID: 30050129.
Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, Langley RR, Jennings NB, Ivan C, Coffin JE, Armaiz GN, Bottsford-Miller J, Kim SB, Halleck MS, Hendrix MJ, Bornman W, Bar-Eli M, Lee JS, Siddik ZH, Lopez-Berestein G, Sood AK. ATP11B mediates platinum resistance in ovarian cancer. J Clin Invest 128(7):3199, 2018. e-Pub 2018. PMID: 29809169.
Allen JK, Armaiz-Pena GN, Nagaraja AS, Sadaoui NC, Ortiz T, Dood R, Ozcan M, Herder DM, Haemmerle M, Gharpure KM, Rupaimoole R, Previs RA, Wu SY, Pradeep S, Xu X, Han HD, Zand B, Dalton HJ, Taylor M, Hu W, Bottsford-Miller J, Moreno-Smith M, Kang Y, Mangala LS, Rodriguez-Aguayo C, Sehgal V, Spaeth EL, Ram PT, Wong STC, Marini FC, Lopez-Berestein G, Cole SW, Lutgendorf SK, De Biasi M, Sood AK. Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction. Cancer Res 78(12):3233-3242, 2018. e-Pub 2018. PMID: 29661830.
Zhang P, Xiao Z, Wang S, Zhang M, Wei Y, Hang Q, Kim J, Yao F, Rodriguez-Aguayo C, Ton BN, Lee M, Wang Y, Zhou Z, Zeng L, Hu X, Lawhon SE, Siverly AN, Su X, Li J, Xie X, Cheng X, Liu LC, Chang HW, Chiang SF, Lopez-Berestein G, Sood AK, Chen J, You MJ, Sun SC, Liang H, Huang Y, Yang X, Sun D, Sun Y, Hung MC, Ma L. ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer. Cell Rep 23(3):823-837, 2018. e-Pub 2018. PMID: 29669287.
Berger AC, Korkut A, Kanchi RS, Hegde AM, Lenoir W, Liu W, Liu Y, Fan H, Shen H, Ravikumar V, Rao A, Schultz A, Li X, Sumazin P, Williams C, Mestdagh P, Gunaratne PH, Yau C, Bowlby R, Robertson AG, Tiezzi DG, Wang C, Cherniack AD, Godwin AK, Kuderer NM, Rader JS, Zuna RE, Sood AK, Lazar AJ, Ojesina AI, Adebamowo C, Adebamowo SN, Baggerly KA, Chen TW, Chiu HS, Lefever S, Liu L, MacKenzie K, Orsulic S, Roszik J, Shelley CS, Song Q, Vellano CP, Wentzensen N, Research Network CGA, Weinstein JN, Mills GB, Levine DA, Akbani R. A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer Cell 33(4):690-705.e9, 2018. e-Pub 2018. PMID: 29622464.
Chiu HS, Somvanshi S, Patel E, Chen TW, Singh VP, Zorman B, Patil SL, Pan Y, Chatterjee SS, Research Network CGA, Sood AK, Gunaratne PH, Sumazin P. Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context. Cell Rep 23(1):297-312.e12, 2018. e-Pub 2018. PMID: 29617668.
Ha JH, Radhakrishnan R, Jayaraman M, Yan M, Ward JD, Fung KM, Moxley K, Sood AK, Isidoro C, Mukherjee P, Song YS, Dhanasekaran DN. LPA Induces Metabolic Reprogramming in Ovarian Cancer via a Pseudohypoxic Response. Cancer Res 78(8):1923-1934, 2018. e-Pub 2018. PMID: 29386184.
Chen X, Mangala LS, Rodriguez-Aguayo C, Kong X, Lopez-Berestein G, Sood AK. RNA interference-based therapy and its delivery systems. Cancer Metastasis Rev 37(1):107-124, 2018. e-Pub 2018. PMID: 29243000.
Lutgendorf SK, Thaker PH, Arevalo JM, Goodheart MJ, Slavich GM, Sood AK, Cole SW. Biobehavioral modulation of the exosome transcriptome in ovarian carcinoma. Cancer 124(3):580-586, 2018. e-Pub 2018. PMID: 29112229.
Mitamura T, Pradeep S, McGuire M, Wu SY, Ma S, Hatakeyama H, Lyons YA, Hisamatsu T, Noh K, Villar-Prados A, Chen X, Ivan C, Rodriguez-Aguayo C, Hu W, Lopez-Berestein G, Coleman RL, Sood AK. Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP). Oncogene 37(6):722-731, 2018. e-Pub 2018. PMID: 29059175.
Huang Y, Hu W, Huang J, Shen F, Sun Y, Ivan C, Pradeep S, Dood R, Haemmerle M, Jiang D, Mangala LS, Noh K, Hansen JM, Dalton HJ, Previs RA, Nagaraja AS, McGuire M, Jennings NB, Broaddus R, Coleman RL, Sood AK. Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer. Mol Cancer Ther 17(2):464-473, 2018. e-Pub 2018. PMID: 29237804.
Leung CS, Yeung TL, Yip KP, Wong KK, Ho SY, Mangala LS, Sood AK, Lopez-Berestein G, Sheng J, Wong ST, Birrer MJ, Mok SC. Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance. J Clin Invest 128(2):589-606, 2018. e-Pub 2018. PMID: 29251630.
Zheng Y, Sethi R, Mangala LS, Taylor C, Goldsmith J, Wang M, Masuda K, Karaminejadranjbar M, Mannion D, Miranda F, Herrero-Gonzalez S, Hellner K, Chen F, Alsaadi A, Albukhari A, Fotso DC, Yau C, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Knapp S, Gray NS, Campo L, Myers KA, Dhar S, Ferguson D, Bast RC, Sood AK, von Delft F, Ahmed AA. Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation. Nat Commun 9(1):476, 2018. e-Pub 2018. PMID: 29396402.
Richardson DL, Sill MW, Coleman RL, Sood AK, Pearl ML, Kehoe SM, Carney ME, Hanjani P, Van Le L, Zhou XC, Alvarez Secord A, Gray HJ, Landrum LM, Lankes HA, Hu W, Aghajanian C. Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial. JAMA Oncol 4(2):196-202, 2018. e-Pub 2018. PMID: 29242937.
Lu Y, Hu Z, Mangala LS, Stine ZE, Hu X, Jiang D, Xiang Y, Zhang Y, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, DeMarzo AM, Sood AK, Zhang L, Dang CV. MYC targeted long non-coding RNA DANCR promotes cancer in part by reducing p21 levels. Cancer Res 78(1):64-74, 2018. e-Pub 2018. PMID: 29180471.
Liu Y, Choi DS, Sheng J, Ensor JE, Liang DH, Rodriguez-Aguayo C, Polley A, Benz S, Elemento O, Verma A, Cong Y, Wong H, Qian W, Li Z, Granados-Principal S, Lopez-Berestein G, Landis MD, Rosato RR, Dave B, Wong S, Marchetti D, Sood AK, Chang JC. HN1L Promotes Triple-Negative Breast Cancer Stem Cells through LEPR-STAT3 Pathway. Stem Cell Reports 10(1):212-227, 2018. e-Pub 2018. PMID: 29249663.
Velazquez-Torres G, Shoshan E, Ivan C, Huang L, Fuentes-Mattei E, Paret H, Kim SJ, Rodriguez-Aguayo C, Xie V, Brooks D, Jones SJM, Robertson AG, Calin G, Lopez-Berenstein G, Sood AK, Bar-Eli M. A-to-I miR-378a-3p editing can prevent melanoma progression via regulation of PARVA expression. Nat Commun 9(1):461, 2018. e-Pub 2018. PMID: 29386624.
Wang S, Liang K, Hu Q, Li P, Song J, Yang Y, Yao J, Mangala LS, Li C, Yang W, Park PK, Hawke DH, Zhou J, Zhou Y, Xia W, Hung MC, Marks JR, Gallick GE, Lopez-Berestein G, Flores ER, Sood AK, Huang S, Yu D, Yang L, Lin C. JAK2-binding long noncoding RNA promotes breast cancer brain metastasis. J Clin Invest 127(12):4498-4515, 2017. e-Pub 2017. PMID: 29130936.
Noh K, Mangala LS, Han HD, Zhang N, Pradeep S, Wu SY, Ma S, Mora E, Rupaimoole R, Jiang D, Wen Y, Shahzad MMK, Lyons Y, Cho M, Hu W, Nagaraja AS, Haemmerle M, Mak CSL, Chen X, Gharpure KM, Deng H, Xiong W, Kingsley CV, Liu J, Jennings N, Birrer MJ, Bouchard RR, Lopez-Berestein G, Coleman RL, An Z, Sood AK. Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis. Cell Rep 21(10):2785-2795, 2017. e-Pub 2017. PMID: 29212026.
Kanlikilicer P, Ozpolat B, Aslan B, Bayraktar R, Gurbuz N, Rodriguez-Aguayo C, Bayraktar E, Denizli M, Gonzalez-Villasana V, Ivan C, Lokesh GLR, Amero P, Catuogno S, Haemmerle M, Wu SY, Mitra R, Gorenstein DG, Volk DE, de Franciscis V, Sood AK, Lopez-Berestein G. Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models. Mol Ther Nucleic Acids 9:251-262, 2017. e-Pub 2017. PMID: 29246304.
Nilsson MB, Sun H, Diao L, Tong P, Liu D, Li L, Fan Y, Poteete A, Lim SO, Howells K, Haddad V, Gomez D, Tran H, Pena GA, Sequist LV, Yang JC, Wang J, Kim ES, Herbst R, Lee JJ, Hong WK, Wistuba I, Hung MC, Sood AK, Heymach JV. Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers. Sci Transl Med 9(415), 2017. e-Pub 2017. PMID: 29118262.
Wang Y, Hu L, Ji P, Teng F, Tian W, Liu Y, Cogdell D, Liu J, Sood AK, Broaddus R, Xue F, Zhang W. Erratum to: MIIP remodels Rac1-mediated cytoskeleton structure in suppression of endometrial cancer metastasis. J Hematol Oncol 10(1):163, 2017. e-Pub 2017. PMID: 28985752.
Cho MS, Noh K, Haemmerle M, Li D, Park H, Hu Q, Hisamatsu T, Mitamura T, Mak SLC, Kunapuli S, Ma Q, Sood AK, Afshar-Kharghan V. Role of ADP receptors on platelets in the growth of ovarian cancer. Blood 130(10):1235-1242, 2017. e-Pub 2017. PMID: 28679740.
Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, Wang Y, Baggerly K, Ram P, Lopez-Berestein G, Liu J, Mok SC, Cohen L, Lutgendorf SK, Cole SW, Sood AK. Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight 2(16). e-Pub 2017. PMID: 28814667.
Haemmerle M, Taylor ML, Gutschner T, Pradeep S, Cho MS, Sheng J, Lyons YM, Nagaraja AS, Dood RL, Wen Y, Mangala LS, Hansen JM, Rupaimoole R, Gharpure KM, Rodriguez-Aguayo C, Yim SY, Lee JS, Ivan C, Hu W, Lopez-Berestein G, Wong ST, Karlan BY, Levine DA, Liu J, Afshar-Kharghan V, Sood AK. Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. Nat Commun 8(1):310, 2017. e-Pub 2017. PMID: 28827520.
Previs RA, Armaiz-Pena GN, Ivan C, Dalton HJ, Rupaimoole R, Hansen JM, Lyons Y, Huang J, Haemmerle M, Wagner MJ, Gharpure KM, Nagaraja AS, Filant J, McGuire MH, Noh K, Dorniak PL, Linesch SL, Mangala LS, Pradeep S, Wu SY, Sood AK. Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies. J Natl Cancer Inst 109(7), 2017. e-Pub 2017. PMID: 28376174.
Wang Y, Xu X, Yu S, Jeong KJ, Zhou Z, Han L, Tsang YH, Li J, Chen H, Mangala LS, Yuan Y, Eterovic AK, Lu Y, Sood AK, Scott KL, Mills GB, Liang H. Systematic characterization of A-to-I RNA editing hotspots in microRNAs across human cancers. Genome Res 27(7):1112-1125, 2017. e-Pub 2017. PMID: 28411194.
Sans M, Gharpure K, Tibshirani R, Zhang J, Liang L, Liu J, Young JH, Dood RL, Sood AK, Eberlin LS. Metabolic Markers and Statistical Prediction of Serous Ovarian Cancer Aggressiveness by Ambient Ionization Mass Spectrometry Imaging. Cancer Res 77(11):2903-2913, 2017. e-Pub 2017. PMID: 28416487.
Sarkar S, Bristow CA, Dey P, Rai K, Perets R, Ramirez-Cardenas A, Malasi S, Huang-Hobbs E, Haemmerle M, Wu SY, McGuire M, Protopopov A, Jiang S, Liu JF, Hirsch MS, Chang Q, Lazar AJ, Sood AK, Drapkin R, DePinho R, Draetta G, Chin L. PRKCI promotes immune suppression in ovarian cancer. Genes Dev 31(11):1109-1121, 2017. e-Pub 2017. PMID: 28698296.
Wagner MJ, Mitra R, McArthur MJ, Baze W, Barnhart K, Wu SY, Rodriguez-Aguayo C, Zhang X, Coleman RL, Lopez-Berestein G, Sood AK. Preclinical mammalian safety studies of EPHARNA (DOPC nanoliposomal EphA2-targeted siRNA). Mol Cancer Ther 16(6):1114-1123, 2017. e-Pub 2017. PMID: 28265009.
Court KA, Hatakeyama H, Wu SY, Lingegowda MS, Rodríguez-Aguayo C, López-Berestein G, Ju-Seog L, Rinaldi C, Juan EJ, Sood AK, Torres-Lugo M. HSP70 inhibition synergistically enhances the effects of magnetic fluid hyperthermia in ovarian cancer. Mol Cancer Ther 16(5):966-976, 2017. e-Pub 2017. PMID: 28223424.
Seviour EG, Sehgal V, Mishra D, Rupaimoole R, Rodriguez-Aguayo C, Lopez-Berestein G, Lee JS, Sood AK, Kim MP, Mills GB, Ram PT. Targeting KRas-dependent tumour growth, circulating tumour cells and metastasis in vivo by clinically significant miR-193a-3p. Oncogene 36(10):1339-1350, 2017. e-Pub 2017. PMID: 27669434.
Harjes U, Bridges E, Gharpure KM, Roxanis I, Sheldon H, Miranda F, Mangala LS, Pradeep S, Lopez-Berestein G, Ahmed A, Fielding B, Sood AK, Harris AL. Antiangiogenic and tumour inhibitory effects of downregulating tumour endothelial FABP4. Oncogene 36(7):912-921, 2017. e-Pub 2017. PMID: 27568980.
Yatsenko SA, Mittal P, Wood-Trageser MA, Jones MW, Surti U, Edwards RP, Sood AK, Rajkovic A. Highly heterogeneous genomic landscape of uterine leiomyomas by whole exome sequencing and genome-wide arrays. Fertil Steril 107(2):457-466.e9, 2017. e-Pub 2017. PMID: 27889101.
Sun Y, Ji P, Chen T, Zhou X, Yang D, Guo Y, Liu Y, Hu L, Xia D, Liu Y, Multani AS, Shmulevich I, Kucherlapati R, Kopetz S, Sood AK, Hamilton SR, Sun B, Zhang W. MIIP attenuation in colorectal cancer induces chromosome instability and promotes tumorigenesis and disease progression. J Pathol 241(1):67-79, 2017. e-Pub 2017. PMID: 27741356.
Rodriguez-Aguayo C, Monroig PDC, Redis RS, Bayraktar E, Almeida MI, Ivan C, Fuentes-Mattei E, Rashed MH, Chavez-Reyes A, Ozpolat B, Mitra R, Sood AK, Calin GA, Lopez-Berestein G. Regulation of hnRNPA1 by microRNAs controls the miR-18a-K-RASaxis in chemotherapy-resistant ovarian cancer. Cell Discov 3:17029, 2017. e-Pub 2017. PMID: 28904816.
Wagner MJ, Ravi V, Menter DG, Sood AK. Endothelial cell malignancies: new insights from the laboratory and clinic. NPJ Precis Oncol 1(1):11, 2017. e-Pub 2017. PMID: 29872699.
Yang L, Achreja A, Yeung TL, Mangala LS, Jiang D, Han C, Baddour J, Marini JC, Ni J, Nakahara R, Wahlig S, Chiba L, Kim SH, Morse J, Pradeep S, Nagaraja AS, Haemmerle M, Kyunghee N, Derichsweiler M, Plackemeier T, Mercado-Uribe I, Lopez-Berestein G, Moss T, Ram PT, Liu J, Lu X, Mok SC, Sood AK, Nagrath D. Targeting Stromal Glutamine Synthetase in Tumors Disrupts Tumor Microenvironment-Regulated Cancer Cell Growth. Cell Metab 24(5):685-700, 2016. e-Pub 2016. PMID: 27829138.
Yokoyama Y, Zhu H, Lee JH, Kossenkov AV, Wu SY, Wickramasinghe JM, Yin X, Palozola KC, Gardini A, Showe LC, Zaret KS, Liu Q, Speicher D, Conejo-Garcia JR, Bradner JE, Zhang Z, Sood AK, Ordog T, Bitler BG, Zhang R. BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer. Cancer Res 76(21):6320-6330, 2016. e-Pub 2016. PMID: 27803105.
Hatakeyama H, Wu SY, Lyons YA, Pradeep S, Wang W, Huang Q, Court KA, Liu T, Nie S, Rodriguez-Aguayo C, Shen F, Huang Y, Hisamatsu T, Mitamura T, Jennings N, Shim J, Dorniak PL, Mangala LS, Petrillo M, Petyuk VA, Schepmoes AA, Shukla AK, Torres-Lugo M, Lee JS, Rodland KD, Fagotti A, Lopez-Berestein G, Li C, Sood AK. Role of CTGF in Sensitivity to Hyperthermia in Ovarian and Uterine Cancers. Cell Rep 17(6):1621-1631, 2016. e-Pub 2016. PMID: 27806300.
Zhou M, Melancon M, Stafford RJ, Li J, Nick AM, Tian M, Sood AK, Li C. Precision Nanomedicine Using Dual Positron Emission Tomography and Magnetic Resonance Temperature Imaging-Guided Photothermal Therapy. J Nucl Med 57(11):1778-1783, 2016. e-Pub 2016. PMID: 27283932.
Wang Y, Hu L, Ji P, Teng F, Tian W, Liu Y, Cogdell D, Liu J, Sood AK, Broaddus R, Xue F, Zhang W. MIIP remodels Rac1-mediated cytoskeleton structure in suppression of endometrial cancer metastasis. J Hematol Oncol 9(1):112, 2016. e-Pub 2016. PMID: 27760566.
Abeydeera ND, Egli M, Cox N, Mercier K, Conde JN, Pallan PS, Mizurini DM, Sierant M, Hibti FE, Hassell T, Wang T, Liu FW, Liu HM, Martinez C, Sood AK, Lybrand TP, Frydman C, Monteiro RQ, Gomer RH, Nawrot B, Yang X. Evoking picomolar binding in RNA by a single phosphorodithioate linkage. Nucleic Acids Res 44(17):8052-64, 2016. e-Pub 2016. PMID: 27566147.
Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. Nat Rev Dis Primers 2:16061, 2016. e-Pub 2016. PMID: 27558151.
Rupaimoole R, Ivan C, Yang D, Gharpure KM, Wu SY, Pecot CV, Previs RA, Nagaraja AS, Armaiz-Pena GN, McGuire M, Pradeep S, Mangala LS, Rodriguez-Aguayo C, Huang L, Bar-Eli M, Zhang W, Lopez-Berestein G, Calin GA, Sood AK. Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression. Oncogene 35(33):4312-20, 2016. e-Pub 2016. PMID: 26725326.
Miranda F, Mannion D, Liu S, Zheng Y, Mangala LS, Redondo C, Herrero-Gonzalez S, Xu R, Taylor C, Chedom DF, Karaminejadranjbar M, Albukhari A, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Salah E, Abdul Azeez KR, Elkins JM, Campo L, Myers KA, Klotz D, Bivona S, Dhar S, Bast RC, Saya H, Choi HG, Gray NS, Fischer R, Kessler BM, Yau C, Sood AK, Motohara T, Knapp S, Ahmed AA. Salt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic Niche. Cancer Cell 30(2):273-289, 2016. e-Pub 2016. PMID: 27478041.
Key NS, Khorana AA, Mackman N, McCarty OJ, White GC, Francis CW, McCrae KR, Palumbo JS, Raskob GE, Chan AT, Sood AK. Thrombosis in Cancer: Research Priorities Identified by a National Cancer Institute/National Heart, Lung, and Blood Institute Strategic Working Group. Cancer Res 76(13):3671-5, 2016. e-Pub 2016. PMID: 27527638.
Huang J, Hu W, Hu L, Previs RA, Dalton HJ, Yang XY, Sun Y, McGuire M, Rupaimoole R, Nagaraja AS, Kang Y, Liu T, Nick AM, Jennings NB, Coleman RL, Jaffe RB, Sood AK. Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth. Mol Cancer Ther 15(6):1344-52, 2016. e-Pub 2016. PMID: 27009216.
Napoli M, Venkatanarayan A, Raulji P, Meyers BA, Norton W, Mangala LS, Sood AK, Rodriguez-Aguayo C, Lopez-Berestein G, Vin H, Duvic M, Tetzlaff MB, Curry JL, Rook AH, Abbas HA, Coarfa C, Gunaratne PH, Tsai KY, Flores ER. ∆Np63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer. Cancer Cell 29(6):874-888, 2016. e-Pub 2016. PMID: 27300436.
Chaluvally-Raghavan P, Jeong KJ, Pradeep S, Silva AM, Yu S, Liu W, Moss T, Rodriguez-Aguayo C, Zhang D, Ram P, Liu J, Lu Y, Lopez-Berestein G, Calin GA, Sood AK, Mills GB. Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer. Cell Rep 15(7):1493-504, 2016. e-Pub 2016. PMID: 27160903.
Nagaraja AS, Dorniak PL, Sadaoui NC, Kang Y, Lin T, Armaiz-Pena G, Wu SY, Rupaimoole R, Allen JK, Gharpure KM, Pradeep S, Zand B, Previs RA, Hansen JM, Ivan C, Rodriguez-Aguayo C, Yang P, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK. Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis. Oncogene 35(18):2390-7, 2016. e-Pub 2016. PMID: 26257064.
Haemmerle M, Bottsford-Miller J, Pradeep S, Taylor ML, Choi HJ, Hansen JM, Dalton HJ, Stone RL, Cho MS, Nick AM, Nagaraja AS, Gutschner T, Gharpure KM, Mangala LS, Rupaimoole R, Han HD, Zand B, Armaiz-Pena GN, Wu SY, Pecot CV, Burns AR, Lopez-Berestein G, Afshar-Kharghan V, Sood AK. FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. J Clin Invest 126(5):1885-96, 2016. e-Pub 2016. PMID: 27064283.
Timsah Z, Ahmed Z, Ivan C, Berrout J, Gagea M, Zhou Y, Pena GN, Hu X, Vallien C, Kingsley CV, Lu Y, Hancock JF, Liu J, Gladden AB, Mills GB, Lopez-Berestein G, Hung MC, Sood AK, Bogdanov M, Ladbury JE. Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancer. Oncogene 35(17):2186-96, 2016. e-Pub 2016. PMID: 26212011.
Han HD, Cho YJ, Cho SK, Byeon Y, Jeon HN, Kim HS, Kim BG, Bae DS, Lopez-Berestein G, Sood AK, Shin BC, Park YM, Lee JW. Linalool-Incorporated Nanoparticles as a Novel Anticancer Agent for Epithelial Ovarian Carcinoma. Mol Cancer Ther 15(4):618-27, 2016. e-Pub 2016. PMID: 26861249.
Wu SY, Rupaimoole R, Shen F, Pradeep S, Pecot CV, Ivan C, Nagaraja AS, Gharpure KM, Pham E, Hatakeyama H, McGuire MH, Haemmerle M, Vidal-Anaya V, Olsen C, Rodriguez-Aguayo C, Filant J, Ehsanipour EA, Herbrich SM, Maiti SN, Huang L, Kim JH, Zhang X, Han HD, Armaiz-Pena GN, Seviour EG, Tucker S, Zhang M, Yang D, Cooper LJ, Ali-Fehmi R, Bar-Eli M, Lee JS, Ram PT, Baggerly KA, Lopez-Berestein G, Hung MC, Sood AK. A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. Nat Commun 7:11169, 2016. e-Pub 2016. PMID: 27041221.
Jung KH, Zhang J, Zhou C, Shen H, Gagea M, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Beretta L. Differentiation therapy for hepatocellular carcinoma: Multifaceted effects of miR-148a on tumor growth and phenotype and liver fibrosis. Hepatology 63(3):864-79, 2016. e-Pub 2016. PMID: 26599259.
Seviour EG, Sehgal V, Lu Y, Luo Z, Moss T, Zhang F, Hill SM, Liu W, Maiti SN, Cooper L, Azencot R, Lopez-Berestein G, Rodriguez-Aguayo C, Roopaimoole R, Pecot CV, Pecot C, Sood AK, Mukherjee S, Gray JW, Mills GB, Ram PT. Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer. Oncogene 35(6):691-701, 2016. e-Pub 2016. PMID: 25639871.
Nagaraja AS, Sadaoui NC, Dorniak PL, Lutgendorf SK, Sood AK. SnapShot: Stress and Disease. Cell Metab 23(2):388-388.e1, 2016. e-Pub 2016. PMID: 26863488.
Zand B, Previs RA, Zacharias NM, Rupaimoole R, Mitamura T, Nagaraja AS, Guindani M, Dalton HJ, Yang L, Baddour J, Achreja A, Hu W, Pecot CV, Ivan C, Wu SY, McCullough CR, Gharpure KM, Shoshan E, Pradeep S, Mangala LS, Rodriguez-Aguayo C, Wang Y, Nick AM, Davies MA, Armaiz-Pena G, Liu J, Lutgendorf SK, Baggerly KA, Eli MB, Lopez-Berestein G, Nagrath D, Bhattacharya PK, Sood AK. Role of Increased n-acetylaspartate Levels in Cancer. J Natl Cancer Inst 108(6):djv426, 2016. e-Pub 2016. PMID: 26819345.
Park YY, Sohn BH, Johnson RL, Kang MH, Kim SB, Shim JJ, Mangala LS, Kim JH, Yoo JE, Rodriguez-Aguayo C, Pradeep S, Hwang JE, Jang HJ, Lee HS, Rupaimoole R, Lopez-Berestein G, Jeong W, Park IS, Park YN, Sood AK, Mills GB, Lee JS. YAP1 and TAZ Activates mTORC1 Pathway by Regulating Amino Acid Transporters in hepatocellular carcinoma. Hepatology 63(1):159-72, 2016. e-Pub 2016. PMID: 26389641.
Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD, Adeli K, Adhihetty PJ, Adler SG, Agam G, Agarwal R, Aghi MK, Agnello M, Agostinis P, Aguilar PV, Aguirre-Ghiso J, Airoldi EM, Ait-Si-Ali S, Akematsu T, Akporiaye ET, Al-Rubeai M, Albaiceta GM, Albanese C, Albani D, Albert ML, Aldudo J, Algül H, Alirezaei M, Alloza I, Almasan A, Almonte-Beceril M, Alnemri ES, Alonso C, Altan-Bonnet N, Altieri DC, Alvarez S, Alvarez-Erviti L, Alves S, Amadoro G, Amano A, Amantini C, Ambrosio S, Amelio I, Amer AO, Amessou M, Amon A, An Z, Anania FA, Andersen SU, Andley UP, Andreadi CK, Andrieu-Abadie N, Anel A, Ann DK, Anoopkumar-Dukie S, Antonioli M, Aoki H, Apostolova N, Aquila S, Aquilano K, Araki K, Arama E, Aranda A, Araya J, Arcaro A, Arias E, Arimoto H, Ariosa AR, Armstrong JL, Arnould T, Arsov I, Asanuma K, Askanas V, Asselin E, Atarashi R, Atherton SS, Atkin JD, Attardi LD, Auberger P, Auburger G, Aurelian L, Autelli R, Avagliano L, Avantaggiati ML, Avrahami L, Awale S, Azad N, Bachetti T, Backer JM, Bae DH, Bae JS, Bae ON, Bae SH, Baehrecke EH, Baek SH, Baghdiguian S, Bagniewska-Zadworna A, Bai H, Bai J, Bai XY, Bailly Y, Balaji KN, Balduini W, Ballabio A, Balzan R, Banerjee R, Bánhegyi G, Bao H, Barbeau B, Barrachina MD, Barreiro E, Bartel B, Bartolomé A, Bassham DC, Bassi MT, Bast RC, Basu A, Batista MT, Batoko H, Battino M, Bauckman K, Baumgarner BL, Bayer KU, Beale R, Beaulieu JF, Beck GR, Becker C, Beckham JD, Bédard PA, Bednarski PJ, Begley TJ, Behl C, Behrends C, Behrens GM, Behrns KE, Bejarano E, Belaid A, Belleudi F, Bénard G, Berchem G, Bergamaschi D, Bergami M, Berkhout B, Berliocchi L, Bernard A, Bernard M, Bernassola F, Bertolotti A, Bess AS, Besteiro S, Bettuzzi S, Bhalla S, Bhattacharyya S, Bhutia SK, Biagosch C, Bianchi MW, Biard-Piechaczyk M, Billes V, Bincoletto C, Bingol B, Bird SW, Bitoun M, Bjedov I, Blackstone C, Blanc L, Blanco GA, Blomhoff HK, Boada-Romero E, Böckler S, Boes M, Boesze-Battaglia. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 12(1):1-222, 2016. e-Pub 2016. PMID: 26799652.
Kanlikilicer P, Saber M, Bayraktar R, Mitra R, Ivan C, Aslan B, Zhang X, Filant J, Silva AM, Rodriguez-Aguayo C, Bayraktar E, Pichler M, Ozpolat B, Calin GA, Sood AK, Lopez-Berestein G. Ubiquitous release of exosomal tumor suppressor miR-6126 from ovarian cancer cells. Cancer Res 76(24), 2016. e-Pub 2016. PMID: 27742688.
Han HD, Byeon Y, Kang TH, Jung ID, Lee JW, Shin BC, Lee YJ, Sood AK, Park YM. Toll-like receptor 3-induced immune response by poly(d,l-lactide-co-glycolide) nanoparticles for dendritic cell-based cancer immunotherapy. Int J Nanomedicine 11:5729-5742, 2016. e-Pub 2016. PMID: 27843314.
Bayer JL, Spitz DR, Christensen D, McCormick ML, Farley D, DeGeest K, Damoush L, Aust S, Sood AK, Lutgendorf SK. Biobehavioral and neuroendocrine correlates of antioxidant enzyme activity in ovarian carcinoma. Brain Behav Immun 50:58-62, 2015. e-Pub 2015. PMID: 25989110.
Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, Brenton JD, Chiappinelli KB, Martins FC, Coukos G, Drapkin R, Edmondson R, Fotopoulou C, Gabra H, Galon J, Gourley C, Heong V, Huntsman DG, Iwanicki M, Karlan BY, Kaye A, Lengyel E, Levine DA, Lu KH, McNeish IA, Menon U, Narod SA, Nelson BH, Nephew KP, Pharoah P, Powell DJ, Ramos P, Romero IL, Scott CL, Sood AK, Stronach EA, Balkwill FR. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer 15(11):668-79, 2015. e-Pub 2015. PMID: 26493647.
Davis LZ, Slavich GM, Thaker PH, Goodheart MJ, Bender DP, Dahmoush L, Farley DM, Markon KE, Penedo FJ, Lubaroff DM, Cole SW, Sood AK, Lutgendorf SK. Eudaimonic well-being and tumor norepinephrine in patients with epithelial ovarian cancer. Cancer 121(19):3543-50, 2015. e-Pub 2015. PMID: 26096769.
Watkins JL, Thaker PH, Nick AM, Ramondetta LM, Kumar S, Urbauer DL, Matsuo K, Squires KC, Coleman RL, Lutgendorf SK, Ramirez PT, Sood AK. Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer. Cancer 121(19):3444-51, 2015. e-Pub 2015. PMID: 26301456.
Reyes-González JM, Armaiz-Peña GN, Mangala LS, Valiyeva F, Ivan C, Pradeep S, Echevarría-Vargas IM, Rivera-Reyes A, Sood AK, Vivas-Mejía PE. Targeting c-MYC in platinum-resistant ovarian cancer. Mol Cancer Ther 14(10):2260-9, 2015. e-Pub 2015. PMID: 26227489.
Matsuo K, Hasegawa K, Yoshino K, Murakami R, Hisamatsu T, Stone RL, Previs RA, Hansen JM, Ikeda Y, Miyara A, Hiramatsu K, Enomoto T, Fujiwara K, Matsumura N, Konishi I, Roman LD, Gabra H, Fotopoulou C, Sood AK. Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma. Eur J Cancer 51(14):1978-88, 2015. e-Pub 2015. PMID: 26238017.
Liu Y, Yasukawa M, Chen K, Hu L, Broaddus RR, Ding L, Mardis ER, Spellman P, Levine DA, Mills GB, Shmulevich I, Sood AK, Zhang W. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma. JAMA Oncol 1(4):486-94, 2015. e-Pub 2015. PMID: 26181259.
Liu G, Yang D, Rupaimoole R, Pecot CV, Sun Y, Mangala LS, Li X, Ji P, Cogdell D, Hu L, Wang Y, Rodriguez-Aguayo C, Lopez-Berestein G, Shmulevich I, De Cecco L, Chen K, Mezzanzanica D, Xue F, Sood AK, Zhang W. Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers. J Natl Cancer Inst 107(7), 2015. e-Pub 2015. PMID: 25995442.
Thanapprapasr D, Previs RA, Hu W, Ivan C, Armaiz-Pena GN, Dorniak PL, Hansen JM, Rupaimoole R, Huang J, Dalton HJ, Ali-Fehmi R, Coleman RL, Sood AK. PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer. Mol Cancer Ther 14(6):1466-75, 2015. e-Pub 2015. PMID: 25833835.
Liu Y, Zhang X, Han C, Wan G, Huang X, Ivan C, Jiang D, Rodriguez-Aguayo C, Lopez-Berestein G, Rao PH, Maru DM, Pahl A, He X, Sood AK, Ellis LM, Anderl J, Lu X. TP53 loss creates therapeutic vulnerability in colorectal cancer. Nature 520(7549):697-701, 2015. e-Pub 2015. PMID: 25901683.
Aslan B, Monroig P, Hsu MC, Pena GA, Rodriguez-Aguayo C, Gonzalez-Villasana V, Rupaimoole R, Nagaraja AS, Mangala S, Han HD, Yuca E, Wu SY, Ivan C, Moss TJ, Ram PT, Wang H, Gol-Chambers A, Ozkayar O, Kanlikilicer P, Fuentes-Mattei E, Kahraman N, Pradeep S, Ozpolat B, Tucker S, Hung MC, Baggerly K, Bartholomeusz G, Calin G, Sood AK, Lopez-Berestein G. The ZNF304-integrin axis protects against anoikis in cancer. Nat Commun 6:7351, 2015. e-Pub 2015. PMID: 26081979.
Coleman RL, Moon J, Sood AK, Hu W, Delmore JE, Bonebrake AJ, Anderson GL, Chambers SK, Markman M. Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904. Eur J Cancer 50(9):1638-48, 2014. e-Pub 2014. PMID: 24709487.
Wen Y, Zand B, Ozpolat B, Szczepanski MJ, Lu C, Yuca E, Carroll AR, Alpay N, Bartholomeusz C, Tekedereli I, Kang Y, Rupaimoole R, Pecot CV, Dalton HJ, Hernandez A, Lokshin A, Lutgendorf SK, Liu J, Hittelman WN, Chen WY, Lopez-Berestein G, Szajnik M, Ueno NT, Coleman RL, Sood AK. Antagonism of tumoral prolactin receptor promotes autophagy-related cell death. Cell Rep 7(2):488-500, 2014. e-Pub 2014. PMID: 24703838.
Joshi HP, Subramanian IV, Schnettler EK, Ghosh G, Rupaimoole R, Evans C, Saluja M, Jing Y, Cristina I, Roy S, Zeng Y, Shah VH, Sood AK, Ramakrishnan S. Dynamin 2 along with microRNA-199a reciprocally regulate hypoxia-inducible factors and ovarian cancer metastasis. Proc Natl Acad Sci U S A 111(14):5331-6, 2014. e-Pub 2014. PMID: 24706848.
Cho MS, Vasquez HG, Rupaimoole R, Pradeep S, Wu S, Zand B, Han HD, Rodriguez-Aguayo C, Bottsford-Miller J, Huang J, Miyake T, Choi HJ, Dalton HJ, Ivan C, Baggerly K, Lopez-Berestein G, Sood AK, Afshar-Kharghan V. Autocrine effects of tumor-derived complement. Cell Rep 6(6):1085-95, 2014. e-Pub 2014. PMID: 24613353.
Guo F, Parker Kerrigan BC, Yang D, Hu L, Shmulevich I, Sood AK, Xue F, Zhang W. Post-transcriptional regulatory network of epithelial-to-mesenchymal and mesenchymal-to-epithelial transitions. J Hematol Oncol 7:19, 2014. e-Pub 2014. PMID: 24598126.
Wu SY, Yang X, Gharpure KM, Hatakeyama H, Egli M, McGuire MH, Nagaraja AS, Miyake TM, Rupaimoole R, Pecot CV, Taylor M, Pradeep S, Sierant M, Rodriguez-Aguayo C, Choi HJ, Previs RA, Armaiz-Pena GN, Huang L, Martinez C, Hassell T, Ivan C, Sehgal V, Singhania R, Han HD, Su C, Kim JH, Dalton HJ, Kovvali C, Keyomarsi K, McMillan NA, Overwijk WW, Liu J, Lee JS, Baggerly KA, Lopez-Berestein G, Ram PT, Nawrot B, Sood AK. 2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nat Commun 5:3459, 2014. e-Pub 2014. PMID: 24619206.
Yang L, Moss T, Mangala LS, Marini J, Zhao H, Wahlig S, Armaiz-Pena G, Jiang D, Achreja A, Win J, Roopaimoole R, Rodriguez-Aguayo C, Mercado-Uribe I, Lopez-Berestein G, Liu J, Tsukamoto T, Sood AK, Ram PT, Nagrath D. Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. Mol Syst Biol 10:728, 2014. e-Pub 2014. PMID: 24799285.
Wang H, Heijnen CJ, van Velthoven CT, Willemen HL, Ishikawa Y, Zhang X, Sood AK, Vroon A, Eijkelkamp N, Kavelaars A. Targeting GRK2/Epac1 to prevent transition to chronic pain. J Clin Invest 123(12):5023-5034, 2013. e-Pub 2013. PMID: 24231349.
Kang Y, Hu W, Ivan C, Dalton HJ, Miyake T, Pecot CV, Zand B, Liu T, Huang J, Jennings NB, Rupaimoole R, Taylor M, Pradeep S, Wu SY, Lu C, Wen Y, Huang J, Liu J, Sood AK. Role of Focal Adhesion Kinase in Regulating YB-1-Mediated Paclitaxel Resistance in Ovarian Cancer. J Natl Cancer Inst 105(19):1485-95, 2013. e-Pub 2013. PMID: 24062525.
Clevenger L, Schrepf A, Degeest K, Bender D, Goodheart M, Ahmed A, Dahmoush L, Penedo F, Lucci J, Thaker PH, Mendez L, Sood AK, Slavich GM, Lutgendorf SK. Sleep disturbance, distress, and quality of life in ovarian cancer patients during the first year after diagnosis. Cancer 119(17):3234-41, 2013. e-Pub 2013. PMID: 23797955.
Bodurka DC, Deavers MT, Tian C, Sun CC, Malpica A, Coleman RL, Lu KH, Sood AK, Birrer MJ, Ozols R, Baergen R, Emerson RE, Steinhoff M, Behmaram B, Rasty G, Gershenson DM. Reclassification of serous carcinoma of the ovary using a two-tier grading system: A Gynecologic Oncology Group study. Cancer 118(12):3087-94, 2012. e-Pub 2012. PMID: 22072418.
Cortez V, Mann M, Tekmal S, Suzuki T, Miyata N, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Vadlamudi RK. Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer. Breast Cancer Res 14(4):R108, 2012. e-Pub 2012. PMID: 22812534.
Gaur P, Sceusi EL, Samuel S, Xia L, Fan F, Zhou Y, Lu J, Tozzi F, Lopez-Berestein G, Vivas-Mejia P, Rashid A, Fleming JB, Abdalla EK, Curley SA, Vauthey JN, Sood AK, Yao JC, Ellis LM. Identification of Cancer Stem Cells in Human Gastrointestinal Carcinoid and Neuroendocrine Tumors. Gastroenterology 141(5):1728-37, 2011. e-Pub 2011. PMID: 21806944.
Hu W, Lu C, Dong HH, Huang J, Shen DY, Stone RL, Nick AM, Shahzad MM, Mora E, Jennings NB, Lee SJ, Roh JW, Matsuo K, Nishimura M, Goodman BW, Jaffe RB, Langley RR, Deavers MT, Lopez-Berestein G, Coleman RL, Sood AK. Biological roles of the delta family notch ligand dll4 in tumor and endothelial cells in ovarian cancer. Cancer Res 71(18):6030-9, 2011. e-Pub 2011. PMID: 21795478.
Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA. MicroRNAs in body fluids--the mix of hormones and biomarkers. Nat Rev Clin Oncol 8(8):467-77, 2011. e-Pub 2011. PMID: 21647195.
Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, Brown EN, Lee RT, Meric-Bernstam F, Sood AK, Conzen SD, Hortobagyi GN, Gonzalez-Angulo AM. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 29(19):2645-52, 2011. e-Pub 2011. PMID: 21632501.
Shahzad MM, Mangala LS, Han HD, Lu C, Bottsford-Miller J, Nishimura M, Mora EM, Lee JW, Stone RL, Pecot CV, Thanapprapasr D, Roh JW, Gaur P, Nair MP, Park YY, Sabnis N, Deavers MT, Lee JS, Ellis LM, Lopez-Berestein G, McConathy WJ, Prokai L, Lacko AG, Sood AK. Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia 13(4):309-19, 2011. e-Pub 2011. PMID: 21472135.
Lamkin DM, Lutgendorf SK, Lubaroff D, Sood AK, Beltz TG, Johnson AK. Cancer induces inflammation and depressive-like behavior in the mouse: Modulation by social housing. Brain Behav Immun 25(3):555-64, 2011. e-Pub 2011. PMID: 21182930.
Lutgendorf SK, DeGeest K, Dahmoush L, Farley D, Penedo F, Bender D, Goodheart M, Buekers TE, Mendez L, Krueger G, Clevenger L, Lubaroff DM, Sood AK, Cole SW. Social isolation is associated with elevated tumor norepinephrine in ovarian carcinoma patients. Brain Behav Immun 25(2):250-5, 2011. e-Pub 2011. PMID: 20955777.
Landen CN, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, Miller LD, Mejia PV, Jennings NB, Gershenson DM, Bast RC, Coleman RL, Lopez-Berestein G, Sood AK. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther 9(12):3186-99, 2010. e-Pub 2010. PMID: 20889728.
Lutgendorf SK, Mullen-Houser E, Russell D, Degeest K, Jacobson G, Hart L, Bender D, Anderson B, Buekers TE, Goodheart MJ, Antoni MH, Sood AK, Lubaroff DM. Preservation of immune function in cervical cancer patients during chemoradiation using a novel integrative approach. Brain Behav Immun 24(8):1231-40, 2010. e-Pub 2010. PMID: 20600809.
Sloan EK, Priceman SJ, Cox BF, Yu S, Pimentel MA, Tangkanangnukul V, Arevalo JM, Morizono K, Karanikolas BD, Wu L, Sood AK, Cole SW. The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res 70(18):7042-52, 2010. e-Pub 2010. PMID: 20823155.
Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L, Armaiz-Pena GN, Hu W, Stone RL, Munkarah A, Ravoori MK, Shahzad MM, Lee JW, Mora E, Langley RR, Carroll AR, Matsuo K, Spannuth WA, Schmandt R, Jennings NB, Goodman BW, Jaffe RB, Nick AM, Kim HS, Guven EO, Chen YH, Li LY, Hsu MC, Coleman RL, Calin GA, Denkbas EB, Lim JY, Lee JS, Kundra V, Birrer MJ, Hung MC, Lopez-Berestein G, Sood AK. Regulation of tumor angiogenesis by EZH2. Cancer Cell 18(2):185-97, 2010. e-Pub 2010. PMID: 20708159.
Spannuth WA, Mangala LS, Stone RL, Carroll AR, Nishimura M, Shahzad MM, Lee SJ, Moreno-Smith M, Nick AM, Liu R, Jennings NB, Lin YG, Merritt WM, Coleman RL, Vivas-Mejia PE, Zhou Y, Krasnoperov V, Lopez-Berestein G, Gill PS, Sood AK. Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma. Mol Cancer Ther 9(8):2377-88, 2010. e-Pub 2010. PMID: 20682653.
Ahmed AA, Lu Z, Jennings NB, Etemadmoghadam D, Capalbo L, Jacamo RO, Barbosa-Morais N, Le XF, Study Group AOC, Vivas-Mejia P, Lopez-Berestein G, Grandjean G, Bartholomeusz G, Liao W, Andreeff M, Bowtell D, Glover DM, Sood AK, Bast RC. SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer. Cancer Cell 18(2):109-21, 2010. e-Pub 2010. PMID: 20708153.
Sood AK, Armaiz-Pena GN, Halder J, Nick AM, Stone RL, Hu W, Carroll AR, Spannuth WA, Deavers MT, Allen JK, Han LY, Kamat AA, Shahzad MM, McIntyre BW, Diaz-Montero CM, Jennings NB, Lin YG, Merritt WM, DeGeest K, Vivas-Mejia PE, Lopez-Berestein G, Schaller MD, Cole SW, Lutgendorf SK. Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest 120(5):1515-1523, 2010. e-Pub 2010. PMID: 20389021.
Tanaka T, Mangala LS, Vivas-Mejia PE, Nieves-Alicea R, Mann AP, Mora E, Han HD, Shahzad MM, Liu X, Bhavane R, Gu J, Fakhoury JR, Chiappini C, Lu C, Matsuo K, Godin B, Stone RL, Nick AM, Lopez-Berestein G, Sood AK, Ferrari M. Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res 70(9):3687-96, 2010. e-Pub 2010. PMID: 20430760.
Merritt WM, Nick AM, Carroll AR, Lu C, Matsuo K, Dumble M, Jennings N, Zhang S, Lin YG, Spannuth WA, Kamat AA, Stone RL, Shahzad MM, Coleman RL, Kumar R, Sood AK. Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer. Mol Cancer Ther 9(4):985-95, 2010. e-Pub 2010. PMID: 20371710.
Cole SW, Arevalo JM, Takahashi R, Sloan EK, Lutgendorf SK, Sood AK, Sheridan JF, Seeman TE. Computational identification of gene-social environment interaction at the human IL6 locus. Proc Natl Acad Sci U S A 107(12):5681-6, 2010. e-Pub 2010. PMID: 20176930.
Lee JW, Han HD, Shahzad MM, Kim SW, Mangala LS, Nick AM, Lu C, Langley RR, Schmandt R, Kim HS, Mao S, Gooya J, Fazenbaker C, Jackson D, Tice DA, Landen CN, Coleman RL, Sood AK. Molecularly targeted chemotherapy using a novel EphA2 immunoconjugate in ovarian carcinoma. J Natl Cancer Inst 101(101):1193-1205, 2009. e-Pub 2009. PMID: 19641174.
Lutgendorf SK, McGinn S, Sung CY, Arevalo JM, DeGeest K, Penedo F, Lucci J, Lubaroff, Sood AK, Cole SW. Depression, social support, and beta-adrenergic transcription control in human ovarian cancer. Brain Behav Immun 23(2):176-83, 2009. e-Pub 2009. PMID: 18550328.
Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng JF, Nick AM, Deavers MT, Mourad-Zeidan A, Wang H, Mueller P, Lenburg ME, Gray JW, Mok S, Birrer MJ, Lopez-Berestein G, Coleman RL, Bar-Eli M, Sood AK. Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med 359(25):2641-50, 2008. e-Pub 2008. PMID: 19092150.
Villares GJ, Zigler M, Wang H, Melnikova VO, Wu H, Friedman R, Leslie MC, Vivas-Mejia PE, Lopez-Berestein G, Sood AK, Bar-Eli M. Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Res 68(21):9078-86, 2008. e-Pub 2008. PMID: 18974154.
Landen CN, Kim TJ, Lin YG, Merritt WM, Kamat AA, Han LY, Spannuth WA, Nick AM, Jennings NB, Kinch MS, Tice D, Sood AK. Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer. Neoplasia 10(11):1259-67, 2008. e-Pub 2008. PMID: 18953435.
Lutgendorf SK, Weinrib A, Penedo F, Costanzo E, Henderson P, DeGeest K, Russell D, Kirschbaum C, Sephton S, Sood AK, Lubaroff DM. Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients. J Clin Oncol 26(29):4820-7, 2008. e-Pub 2008. PMID: 18779606.
Gray MJ, Dallas NA, Van Buren G, Xia L, Yang AD, Somcio RJ, Gaur P, Mangala LS, Vivas-Mejia PE, Fan F, Sanguino AM, Gallick GE, Lopez-Berestein G, Sood AK, Ellis LM. Therapeutic targeting of Id2 reduces growth of human colorectal carcinoma in the murine liver. Oncogene 27(57):7192-200, 2008. e-Pub 2008. PMID: 18806828.
Landen CN, Jr, Lu C, Han LY, Coffman KT, Bruckheimer E, Halder J, Mangala LS, Merritt WM, Lin YG, Gao C, Schmandt R, Kamat AA, Li Y, Thaker P, Gershenson DM, Parikh NU, Gallick GE, Kinch MS, Sood AK. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J Natl Cancer Inst 98:1558-70, 2006. e-Pub 2006. PMID: 17077358.
Han LY, Landen CN, Jr, Kamat AA, Lopez A, Bender DP, Mueller P, Schmandt R, Gershenson DM, Sood AK. Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma. J Clin Oncol 24:755-61, 2006. e-Pub 2006. PMID: 16380413.

Review Articles

Matsuo K, Matsuzaki S, Maeda M, Rau AR, Yoshihara K, Tamura R, Shimada M, Machida H, Mikami M, Klar M, Roman LD, Wright JD, Sood AK, Gershenson DM. Uptake and Outcomes of Neoadjuvant Chemotherapy Among US Patients With Less Common Epithelial Ovarian Carcinomas. JAMA Netw Open 6(6):e2318602, 2023. e-Pub 2023. PMID: 37326992.
Corvigno S, Johnson AM, Wong KK, Cho MS, Afshar-Kharghan V, Menter DG, Sood AK. Novel Markers for Liquid Biopsies in Cancer Management: Circulating Platelets and Extracellular Vesicles. Mol Cancer Ther 21(7):1067-1075, 2022. e-Pub 2022. PMID: 35545008.
Liu J, Niu N, Li X, Zhang X, Sood AK. The life cycle of polyploid giant cancer cells and dormancy in cancer: Opportunities for novel therapeutic interventions. Semin Cancer Biol 81:132-144, 2022. e-Pub 2022. PMID: 34670140.
Menter DG, Afshar-Kharghan V, Shen JP, Martch SL, Maitra A, Kopetz S, Honn KV, Sood AK. Of vascular defense, hemostasis, cancer, and platelet biology: an evolutionary perspective. Cancer Metastasis Rev 41(1):147-172, 2022. e-Pub 2022. PMID: 35022962.
LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL. Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol 20(1):e15-e28, 2019. e-Pub 2019. PMID: 30614472.
Zhang L, Peng D, Sood AK, Dang CV, Zhong X. Shedding Light on the Dark Cancer Genomes: Long Noncoding RNAs as Novel Biomarkers and Potential Therapeutic Targets for Cancer. Mol Cancer Ther 17(9):1816-1823, 2018. e-Pub 2018. PMID: 30181330.
Haemmerle M, Stone RL, Menter DG, Afshar-Kharghan V, Sood AK. The Platelet Lifeline to Cancer: Challenges and Opportunities. Cancer Cell 33(6):965-983, 2018. e-Pub 2018. PMID: 29657130.
Menter DG, Kopetz S, Hawk E, Sood AK, Loree JM, Gresele P, Honn KV. Platelet "first responders" in wound response, cancer, and metastasis. Cancer Metastasis Rev 36(2):199-213, 2017. e-Pub 2017. PMID: 28730545.
Lyons YA, Wu SY, Overwijk WW, Baggerly KA, Sood AK. Immune cell profiling in cancer: molecular approaches to cell-specific identification. NPJ Precis Oncol 1(1):26, 2017. e-Pub 2017. PMID: 29872708.
Shah MY, Ferrajoli A, Sood AK, Lopez-Berestein G, Calin GA. microRNA Therapeutics in Cancer - An Emerging Concept. EBioMedicine 12:34-42, 2016. e-Pub 2016. PMID: 27720213.
Hansen JM, Coleman RL, Sood AK. Targeting the tumour microenvironment in ovarian cancer. Eur J Cancer 56:131-43, 2016. e-Pub 2016. PMID: 26849037.
Barata P, Sood AK, Hong DS. RNA-targeted therapeutics in cancer clinical trials: Current status and future directions. Cancer Treat Rev 50:35-47, 2016. e-Pub 2016. PMID: 27612280.
Ozcan G, Ozpolat B, Coleman RL, Sood AK, Lopez-Berestein G. Preclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev 87:108-19, 2015. e-Pub 2015. PMID: 25666164.
Lutgendorf SK, Sood AK, Antoni MH. Host factors and cancer progression: Biobehavioral signaling pathways and interventions. J Clin Oncol 28(26):4094-9, 2010. e-Pub 2010. PMID: 20644093.
Armaiz-Pena GN, Lutgendorf SK, Cole SW, Sood AK. Neuroendocrine modulation of cancer progression. Brain Behav Immun 23(1):10-5, 2009. e-Pub 2009. PMID: 18638541.

Professional Educational Materials

Sood AK. Developed instructional videotapes and written materials for teaching operative dictations to residents and fellows, 2002.

Editorials

MNVR K, Sood AK. Editorial - Metronomic chemotherapy. Cancer Lett 400:203, 2017. PMID: 28315702.
Ravi Kumar MNV, Sood AK. Featuring the Guest Editors. Cancer Lett 400:204, 2017. PMID: 28315431.

Abstracts

Schmeler KM, Jhingran A, Iyer RB, Sun CC, Eifel PJ, Soliman PJ, Ramirez PT, Frumovitz M, Bodurka DC, Sood AK. Pelvic fractures following radiation therapy for cervical cancer: Implications for survivors. 44th Annual Meeting of the American Society of Clinical Oncology, Chicago, 2008.(Abstract 5530, 2008 ASCO Proceedings, Page 300s), 2008. e-Pub 2008.
Buller RE, Sood AK, Hodges K, Lager D. Avoiding misses: Understanding why a p53 target can be elusive. Cancer Gene Therapy: Conference Supplement 4(6):S19, 1997. e-Pub 1997.
Buller RE, Lallas TA, Fullenkamp C, Sood AK. Selective X-chromosome inactivation (SXI) associated with BRCA1 loss of heterozygosity (LOH) is highly predictive of BRCA1 mutation in ovarian carcinoma. Proceedings of the American Association for Cancer Research 38:167. Abstract #1121, 1997. e-Pub 1997.
Sood AK, Knowlton S, Buller RE. Genomic instability in ovarian cancer: A reassessment using arbitrarily primed polymerase chain reaction. Proceedings of the American Association for Cancer Research 37:544. Abstract #3722, 1996. e-Pub 1996.
Sood AK. Proteome Changes Correlating with Neoadjuvant Chemotherapy Response and Residual Disease in Advanced Ovarian Cancers. ASMS Conference on Mass Spectrometry and Allied Topics.
Mostafa Eyada, Victoria Michael, Bryan M. Fellman, Shrina Patel, Pamela T. Soliman, Jeffrey Andrew How, Amir A. Jazaeri, Nicole D. Fleming, Shannon Neville Westin, Travis T. Sims. Oral cyclophosphamide plus bevacizumab in recurrent ovarian, fallopian tube and primary peritoneal cancer. 2024 ASCO Annual Meeting.
Singh N, Goff M, Need E, Sood A, Mourtada F, Mastren T, Goel S, Shi S. Folate Receptor α-Targeted Alpha Therapy of Ovarian Cancer. 19th International Symposium on Recent Advances in Drug Delivery Systems.
Singh N, Goff M, Need E, Sood A, Mourtada F, Mastren T, Goel S, Shi S. Folate Receptor α-Targeted Alpha Therapy of Ovarian Cancer. Society of Nuclear Medicine and Molecular Imaging 2025 Annual Meeting.

Book Chapters

Matsuo, K, Sood, AK, Gershenson, DM. MANAGEMENT OF EARLY-STAGE OVARIAN CANCER, 60-92, 2024.
Westin, SN, Sood, AK, Coleman, R. Targeted therapy and molecular genetics, 464-488, 2023.
Oncul, S, Amero, P, Rodriguez-Aguayo, C, Sood, AK, Calin, GA, Lopez Berestein, G. RNA delivery for cancer gene therapy, 375-424, 2022.
Sood AK, Li Y, Yang S, Hu W. The roles of anoikis in cervical cancer. In: Anoikis: How the extracellular matrix regulates life-or-death decisions. Springer Nature, 2021.
Coleman RL, Liu JS, Matsuo K, Thaker PH, Westin SN, Sood AK. Carcinoma of the ovaries and fallopian tubes. In: Abeloff’s Clinical Oncology, Sixth Edition. Elsevier, 1525 – 1543, 2020.
Zhang J, Silva E, Sood AK, Liu J. Ovarian epithelial carcinogenesis. In: Gynecologic and Obstetric Pathology. Science Press & Springer Nature, Singapore Pte Ltd, 121-139, 2019.
Taki M, Rodriguez-Aguayo C, Mangala LS, Lopez-Berestein G, Sood AK. In: Avances in RNAi-based therapy for cancer, 2019.
Oncul S, Amero P, Rodriguez-Aguayo C, Sood AK, Calin GA, Lopez-Berestein G. RNA delivery for cancer gene therapy. In: RNA Therapeutics. Elsevier, 2019.
Kondetimmanahalli R, Kondetimmanahalli R, Gharpure KM, Gharpure KM, Wu SY, Wu SY, Lopez-Berestein G, Lopez-Berestein G, Sood AK, Sood AK. In: Non-conding RNAs: Novel targets in anti-cancer drug development, 2018.
Menter DG, Davis JS, Tucker SC, Hawk E, Crissman JD, Sood AK, Kopetz S, Honn KV. First responders” in cancer progression and metastasis. In: In- Platelets in Thrombotic and Non-thrombotic Disorders - Pathophysiology, Pharmacology and Therapeutics, 2017.
Hatakeyama H, Wu SY, Mangala LS, Lopez-Berestein G, Sood AK. Assessment of in vivo siRNA delivery in cancer mouse models. In: Long non-coding RNA: Methods and protocols. Methods in Molecular Biology. In: Humana, 189-197, 2016.
Zhang X, Lopez-Berestein G, Sood AK, Calin GA. Profiling long-non coding RNA expression using custom-designed microarray. In: Methods Mol Biol, 33-41, 2016.
Taylor M, Coleman RL, Sood AK. The role of angiogenesis in cancer. In: Targeted Therapy in Translational Cancer Research, 2015.
Thaker PH, Sood AK. Molecular pathogenesis of ovarian cancer. In: Current Multidisciplinary Oncology: Gynecologic Cancer. Demos Medical Publishing, 95-104, 2015.
Jiang D, Mangala LS, Rodriguez-Aguayo C, Gorenstein D, Lopez-Berestein G, Sood AK. Targeting approaches for nanoparticles. In: Nanoparticles for Delivery of Biotherapeutics. In: Future Science Group. Future Science Group, 64-77, 2015.
Kanlikilicer P, Rashed M, Ozpolat B, Ivan C, Rodriguez-Aguayo C, Sood AK, Calin GA, Lopez-Berestein G. The “EX” and the “SOMA”: How they communicate. In: Nano-Oncologicals: New Targeting and Delivery Approaches. In: In: Nano-Oncologicals: New Targeting and Delivery Approaches. Springer, 47 – 66, 2014.
Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK. RNAi in Cancer Therapy. In: Advanced delivery and therapeutic applications of RNA interference. John Wiley & Sons, Inc, 271-307, 2013.
Thaker PH, Sood AK. Immunology and Molecular Oncology in Gynecologic Cancer: Immunologic Response, Cytokines, Oncogenes, and Tumor Suppressor Genes. In: Comprehensive Gynecology. Sixth. Elsevier, 623-634, 2012.
Westin SN, Sood AK, Coleman RL. Targeted therapy and molecular genetics (Chapter 19). In: Clinical Gynecologic Oncology. (8th edition). Elsevier, 539-560, 2012.
Ahmed AA, Knapp S, Sood AK, Bast RC. Targeting therapies in cancer: Opportunities in Ovarian cancer. In: Gynecological Cancers: Biology and Therapeutics. RCOG Press, 167-182, 2011.
Costanzo ES, Sood AK, Lutgendorf SK. Biobehavioral influences on cancer progression. In: Immunol Allergy Clin North Am. 1, 109-32, 2011.
Allen JK, Armaiz-Pena G, Sood AK. Stress and Cancer. In: The M.D. Anderson Manual of Psychosocial Oncology. McGraw Hill, 17-34, 2010.
Matsuo K, Lu C, Shahzad MMK, Coleman RL, Sood AK. Role of pericytes in resistance to anti-angiogenic therapy. In: The Tumor Microenvironment. Springer, 311-324, 2010.
Costanzo E, Sood AK, Lutgendorf SK. Biobehavioral influences on cancer progression. In: Stress and Inflammatory Diseases in Immunology and Allergy Clinics of North America, 31(1):109-132, 2010.
Maxwell GL, Berchuck A, Sood AK. Biology and Genetics. In: Practical Gynecologic Oncology. Fifth. Lippincott Williams & Wilkins, 2009.
Nick AM, Coleman RL, Sood AK. Molecular therapeutics in ovarian carcinoma. In: Ovarian Cancer: State of the Art. Remedica Medical Education and Publishing Limited, Chapter 5, pages 109-160, 2009.
Mangala LS, Han HD, Lopez-Berestein G, Sood AK. Liposomal siRNA for ovarian cancer. In: Methods Mol Biol. Humana Press, 29-42, 2009.
Lu C, Sood AK. Role of pericytes in angiogenesis. In: Angiogenesis Agents in Cancer Therapy. Second. The Humana Press, Inc, 117-132, 2007.
Sood AK, Lin YG, Jaffe RB. Prognostic and predictive implications of angiogenesis in ovarian carcinoma. In: Prognostic and Predictive Factors in Gynecologic Cancers. Taylor & Francis Group, 2007.
Sood AK, Lutgendorf SK, Ben-Eliyahu S. Neuroendocrine regulation of cancer progression: from mechanisms to clinical relevance. In: Psychoneuroimmunology. Fourth, 233-249, 2006.
Sood AK, Gershenson DM. Management of early-stage ovarian cancer (Chapter 3). In: Surgery for ovarian cancer: Principles and Practice. Parthenon Publishing, 57-86, 2006.
Sood AK. Genetics and Cancer. In: Women's Cancer Network (on-line chapter), 2002.
Sood AK, Buller RE. SSCP and sequence analysis of p53 mutation in ovarian tumors. In: Methods in Molecular Medicine: Ovarian Cancer Methods and Protocols. Humana Press, 323-328, 2000.
Sood AK, Sorosky JI. Invasive cervical cancer complicating pregnancy: How to manage the dilemma. In: Obstetrics and Gynecology Clinics of North America, 343-52, 1998.
Sorosky JI, Sood AK, Buekers TE. The use of chemotherapeutic agents during pregnancy. In: Obstetrics and Gynecology Clinics of North America, 591-9, 1997.
Stone RL, Sood AK. Status of targeted/molecular therapy for ovarian cancer. In: Ovarian Cancer: Ask the Experts. Humana Press, Inc.
Sood AK, Matsuo K, Gershenson DM. Management of early-stage ovarian cancer. In: Surgery for ovarian cancer: Principles and practice. Second. Parthenon Publishing.
Mora EM, Mangala LS, Lopez-Berestein G, Sood AK. RNAi: A new paradigm in cancer gene therapy. In: Gene based therapies for Cancer. Springer.
Lutgendorf SK, Costanzo E, Sood AK. Psychoneuroimmunology and cancer: Biobehavioral influences on tumor progression. In: The Oxford Handbook of Psychoneuroimmunology.
Aslan B, Han HD, Lopez-Berestein G, Sood AK. Chitosan nanoparticles. In: Encyclopedia of Nanotechnology. Springer.
Chen A, Zhaoxia D, Sood AK, Hu W. Hormonal therapy for ovarian cancer. In: Encyclopedia of Cancer. Springer.
Alpay SN, Ozpolat B, Han HD, Lopez-Berestein G, Sood AK, Pan HL. Regulation of cell signaling in the nervous system with nanoparticles containing siRNA. In: Nanomedicine and the Nervous System. Science Publishers.
Fleming ND, Coleman RL, Sood AK. Targeted therapies in ovarian cancer. In: Clinical Decisions Support Project.
Liang L, Mercado-Uribe I, Niu N, Jiang Y, Cheng W, Mills GB, Scott C, Sood AK, Liu J. Patient-derived xenograft models of ovarian/gynecologic tumors. In: In: Patient Derived Tumor Xenograft Model. Elsevier.
Denizli M, Aslan B, Rodriguez-Aguayo C, Mangala LS, Jiang D, Lopez-Berestein G, Sood AK. In: Chitosan nanoparticles for miRNA delivery. In: RNA Nanostructures. Methods in Molecular Biology. Humana.
Han LY, Sood AK. Inhibition of the Src Oncogene: Therapeutic potential in ovarian carcinoma. In: Emerging Therapeutics in Cancer.

Books (edited and written)

Co-Editor, Sood A. Prognostic and Predictive Factors in Gynecologic Cancers. Taylor & Francis Group, 2007.
Sood AK, Matsuo K. Management of early stage ovarian cancer - 2nd Edition.

Letters to the Editor

Thaker PH, Urbauer DL, Sood AK. Reply to beta blockers in epithelial ovarian cancer and beta-blockers and improved survival from ovarian cancer: New miracle treatment or another case of immortal person-time bias?. Cancer 122: 325-6, 2016.

Patents

Methods and Composition of Matter Related to Wrapping of Dehydrons (filed: October, 2007; Issued: June 18, 2013; U.S. Patent Number 8,466,154 B2). Patent Number: U.S. Patent Number 8,466,154 B2.
Pro-angiogenic gene in ovarian tumor endothelial cell isolates. Patent Number: (filed: December, 2006; Issued: May 14, 2013; Patent number 8440393).
Methods for treating cancer targeting transglutaminase. Patent Number: (filed October 5, 2007; Issued: October 30, 2012; Patent number 8299040).
Therapeutic targeting of Interleukins using siRNA in neutral liposomes. Patent Number: US 8,067,390 B2.
Novel tissue protective erythropoietin receptor (NEPOR) and methods of use. Patent Number: 2 109 690.
HDL nanoparticles for delivery of nucleic acids. Patent Number: (filed: December, 2007; Issued: May 27, 2014; U.S. Patent Number 8,734,853).
Delivery of siRNA by neutral lipid compositions. Patent Number: 60/671,641 (filing date: April 15, 2005). (Australian patent number 2006236453 issued February 23, 2012; U.S. patent number 8,895,717 issued November 25, 2014).

Less